The present invention concerns methods and means to produce humanized antibodies from transgenic non-human animals. The invention specifically relates to novel immunoglobulin heavy and light chain constructs, recombination and transgenic vectors useful in making transgenic non-human animals expressing humanized antibodies, transgenic animals, and humanized immunoglobulin preparations.
|
1. A b cell from a transgenic rabbit, wherein said transgenic rabbit comprises a humanized immunoglobulin (ig) locus comprising multiple ig gene segments, present in a transgenic vector wherein:
(a) at least one of said gene segments is a human ig gene segment comprising two or more identical or different units consisting of, from 5′ to 3′ direction, a 5′ nucleotide sequence, a human immunoglobulin heavy or light chain V gene segment, and a 3′ nucleotide sequence, wherein said 5′ nucleotide sequence and said 3′ nucleotide sequence have the nucleotide sequence of SEQ ID NO: 35;
(b) said gene segments are juxtaposed in an unrearranged, partially rearranged or fully rearranged configuration, and
(c) said humanized ig locus is capable of undergoing gene rearrangement, if necessary, and gene conversion and/or hypermutation, and producing a repertoire of humanized immunoglobulins in said transgenic rabbit.
2. The b cell of
3. The b cell of
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
This application is a divisional application of U.S. application Ser. No. 12/511,188 filed Jul. 29, 2009, which is a divisional application of U.S. application Ser. No. 10/893,483 filed Jul. 15, 2004 (now U.S. Pat. No. 7,585,668) which claims priority under 35 U.S.C. Section 119(e) and the benefit of U.S. Provisional Application Ser. No. 60/487,733 filed Jul. 15, 2003, the entire disclosures of which are incorporated herein by reference in their entireties.
In accordance with 37 CFR 1.821(e), we hereby expressly incorporate herein by reference, in its entirety, the last-filed (filed Apr. 4, 2005) computer readable Sequence Listing, saved as “39691-0007A saved Apr. 4, 2005.txt” date of creation Apr. 4, 2005, size 1,489 KB, submitted in U.S. application Ser. No. 10/893,483, filed Jul. 15, 2004.
The present invention concerns methods and means to produce humanized antibodies from transgenic non-human animals. The invention specifically relates to novel immunoglobulin heavy and light chain constructs, recombination and transgenic vectors useful in making transgenic non-human animals expressing humanized antibodies, transgenic animals, and humanized immunoglobulin preparations. The transgenic vectors contain humanized immunoglobulin loci, which are capable of undergoing gene rearrangement, gene conversion and hypermutation in transgenic non-human animals to produce diversified humanized antibodies, while leaving the endogenous regulatory and antibody production machinery of the non-human animals essentially intact. The humanized antibodies obtained have minimal immunogenicity to humans and are appropriate for use in the therapeutic treatment of human subjects.
Antibodies are an important class of pharmaceutical products that have been successfully used in the treatment of various human diseases and conditions, such as cancer, allergic diseases, prevention of transplant rejection and host-versus-graft disease.
A major problem of antibody preparations obtained from animals is the intrinsic immunogenicity of non-human immunoglobulins in human patients. In order to reduce the immunogenicity of non-human antibodies, it has been shown that by fusing animal variable (V) region exons with human constant (C) region exons, a chimeric antibody gene can be obtained.
Humanized monoclonal antibodies have also been developed and are in clinical use. Humanized monoclonal antibodies are typically human antibodies in which some CDR residues and possibly some FR residues are substituted by residues from analogous sites in non-human animal, e.g. rodent, antibodies. Humanization can be essentially performed following the method of Winter and co-workers (Jones et al., Nature, 321: 522 (1986); Riechmann et al., Nature, 332: 323 (1988); Verhoeyen et al., Science, 239: 1534 (1988)), by substituting non-human animal, e.g. rodent, CDRs or CDR sequences for the corresponding sequences of a human monoclonal antibody.
It has been described that the homozygous deletion of the antibody heavy-chain joining region (JH) gene in chimeric and germ-line mutant mice results in complete inhibition of endogenous antibody production. Transfer of the human germ-line immunoglobulin gene array in such germ-line mutant mice will result in the production of human antibodies upon antigen challenge. See, e.g., Jakobovits et al., Proc. Natl. Acad. Sci. USA, 90: 2551 (1993); Jakobovits et al., Nature, 362: 255 (1993); Bruggemann et al., Year in Immunol., 7: 33 (1993). While this genetic engineering approach resulted in the expression of human immunoglobulin polypeptides in genetically engineered mice, the level of human immunoglobulin expression is low. This may be due to species-specific regulatory elements in the immunoglobulin loci that are necessary for efficient expression of immunoglobulins. As demonstrated in transfected cell lines, regulatory elements present in human immunoglobulin genes may not function properly in non-human animals.
Indeed, several regulatory elements in immunoglobulin genes have been described. Of particular importance are enhancers downstream (3′) of heavy chain constant regions and intronic enhancers in light chain genes. In addition, other, yet to be identified, control elements may be present in immunoglobulin genes. Studies in mice have shown that the membrane and cytoplasmic tail of the membrane form of immunoglobulin molecules play an important role in expression levels of human-mouse chimeric antibodies in the serum of mice homozygous for the human Cγ1 gene. Therefore, for the expression of heterologous immunoglobulin genes in animals it is desirable to replace sequences that contain enhancer elements and exons encoding transmembrane (M1 exon) and cytoplasmic tail (M2 exon) with sequences that are normally found in the animal in similar positions.
In addition to the issues raised by the potential immunogenicity of the non-human antibodies, the use of monoclonal antibodies in general, whether chimeric, humanized or human, is further limited by the fact that devastating diseases, such as cancer and infections with virulent pathogens, are difficult to treat by attacking one target, due to their complexity, multifactorial etiology and adaptivity. Monoclonal antibodies directed against singularly defined targets fail when those targets change, evolve and mutate. Thus, malignancies may gain resistance to standard monoclonal antibody therapies. A solution to this problem is the use of polyclonal antibodies, which have the ability to target and attack a plurality of evolving targets linked with complex diseases. Polyclonal antibodies also have the ability to neutralize bacterial and viral toxins, and direct immune responses to kill and eliminate pathogens.
Accordingly, there is a great clinical need for a new approach suitable for the large-scale production of high-titer, high-affinity, humanized poly- and monoclonal antibodies.
The introduction of human immunoglobulin genes into the genome of mice resulted in expression of a diversified human antibody repertoire in genetically engineered mice. In both mice and humans, primary antibody diversity is generated by gene rearrangement. This process results in the generation of many different recombined V(D)J segments encoding a large number of antibody molecules with different antigen binding sites. However, in other animals, like rabbits, pigs, cows and birds, primary antibody diversity is generated by substantially different mechanisms, namely templated mutations or gene conversion and non-templated mutations or hypermutation. For example, it is well established that in rabbit and chicken, VDJ rearrangement is very limited (almost 90% of immunoglobulin is generated with the 3′ proximal VH1 element) and antibody diversity is generated by gene conversion and hypermutation. In contrast, mouse and human gene conversion occurs very rarely, if at all. Therefore, it is expected that in animals that diversify their primary antibody repertoire by gene conversion and hypermutation a genetic engineering approach based on gene rearrangement will result in animals with low antibody titers and limited antibody diversity. Thus, the genetic engineering of large animals for the production of non-immunogenic antibody preparations for human therapy requires alternative genetic engineering strategies.
The production of humanized antibodies in transgenic non-human animals is described in PCT Publication No. WO 02/12437, published on Feb. 14, 2002, the disclosure of which is hereby expressly incorporated by reference in its entirety. WO 02/12437 describes genetically engineered non-human animals containing one or more humanized immunoglobulin loci which are capable of undergoing gene rearrangement and gene conversion in transgenic non-human animals, including animals in which antibody diversity is primarily generated by gene conversion to produce diversified humanized antibodies. The humanized antibodies obtained have minimal immunogenicity to humans and are appropriate for use in the therapeutic treatment of human subjects. It further describes novel nucleotide sequences from the 5′ and 3′ flanking regions of immunoglobulin heavy chain constant region segments of various non-human mammalians, such as chickens, cows, sheep, and rabbits. Recombinant vectors in which human immunoglobulin heavy chain gene segments are flanked by sequences homologous to such 5′ and 3′ sequences are shown to be useful for replacing an immunoglobulin heavy chain gene segment of a non-human animal with the corresponding human immunoglobulin heavy chain gene segment.
In one aspect, the present invention concerns an isolated nucleic acid molecule comprising a human immunoglobulin gene segment, flanked by nucleotide sequences, wherein the flanking sequences are identical or different, and comprise at least about 20 contiguous nucleotides of a spacer sequence from an immunoglobulin heavy or light chain gene of an animal generating antibody diversity primarily by gene conversion and/or hypermutation, or from a consensus sequence of two or more of the spacer sequences.
In another aspect, the invention concerns an isolated nucleic acid molecule comprising a human immunoglobulin heavy or light chain constant region (C) gene segment, flanked by nucleotide sequences, wherein the flanking sequences are identical or different, and comprise at least about 20 contiguous nucleotides of a spacer sequence from an immunoglobulin heavy or light chain gene of a non-primate animal, or from a consensus sequence of two or more of the spacer sequences.
In a further aspect, the invention concerns an isolated nucleic acid molecule comprising a human immunoglobulin heavy or light chain gene segment, flanked by nucleotide sequences, wherein the flanking sequences are identical or different, and comprise at least about 20 contiguous nucleotides of a spacer sequence selected from the group consisting of SEQ ID NOS: 1 to 185 (Table 1), or from a consensus sequence of two or more of the spacer sequences.
In one embodiment, the flanking sequences comprise at least about 50 contiguous nucleotides of a spacer sequence.
In another embodiment, the human immunoglobulin gene segment is a heavy chain V, D, or J segment, where the V fragment may, for example be a member of the VH3, VH1, VH5, or VH4 family.
In a further embodiment, the human immunoglobulin gene segment is a light chain V or J segment, where the V segment may, for example be a κ light chain gene segment, such as Vκ1, Vκ3, or Vκ4, or a λ light chain segment, e.g. Vλ1, Vλ2 or Vλ3.
In a further embodiment, the non-primate animal which generates antibody diversity primarily by gene conversion and/or somatic hypermutation is, for example, rabbit, pig, bird, e.g. chicken, turkey, duck, or goose, sheep, goat, cow, horse or donkey, however, other non-primate animals, e.g. rodents are also specifically included within the scope of the invention.
In another aspect, the invention concerns a recombination vector comprising any of the foregoing nucleic acid molecules.
In yet another aspect, the invention concerns a transgenic vector comprising a humanized immunoglobulin (Ig) locus, wherein the humanized Ig locus is derived from an Ig locus or a portion of an Ig locus of a non-human animal, comprising multiple Ig segments wherein
(a) at least one of the gene segments is a human Ig gene segment flanked by nucleotide sequences comprising at least about 20 contiguous nucleotides from a spacer sequence, or from a consensus sequence or two or more of such spacer sequences;
(b) the gene segments are juxtaposed in an unrearranged, partially rearranged or fully rearranged configuration, and
(c) the humanized Ig locus is capable of undergoing gene rearrangement, if necessary, as well as gene conversion and/or hypermutation, if the non-human animal is a gene converting animal, and producing a repertoire of humanized immunoglobulins in the non-human animal.
In a further embodiment, the humanized Ig heavy chain locus present in the transgenic vector comprises about 5 to 100 V gene segments, with at least one human V gene segment. In a specific embodiment, the humanized Ig heavy chain locus comprises more than one human V gene segments.
In another embodiment, the humanized Ig heavy chain locus present in the transgenic vector comprises about 5 to 25 D gene segments, In a specific embodiment, the humanized Ig heavy chain locus comprises one or several human D gene segments.
In yet another embodiment, the humanized Ig heavy chain locus present in the transgenic vector comprises about 1 to 10 J gene segments, with at least one human J gene segment. In a specific embodiment, the humanized Ig heavy chain locus comprises more than one human J gene segments.
In another embodiment, the humanized Ig heavy chain locus present in the transgenic vector comprises about 1-25 C region segments, with at least one human C region segment. In a specific embodiment, the humanized Ig heavy chain locus present in the transgenic vector comprises more than one human C gene segment.
In a still further embodiment, the humanized Ig locus present in the transgenic vector is a light chain locus of a non-human animal, and it comprises at least one V gene segment, at least one J gene segment and at least one constant (C) region gene segment, where at least one gene segment is selected from the group of human light chain V and J segments and human light chain C region segments. In a specific embodiment, the constant region gene segment is a human light chain constant region gene segment, which can, for example, be a Cλ or Cκ gene segment. In another embodiment, the humanized Ig light chain locus comprises two or more segments selected from human V and J segments and human C region segments. In a further embodiment, the humanized Ig light chain locus comprises at least one human V segment, at least one human J segment, and at least one human C region segment.
In a further embodiment, the humanized Ig light chain locus present in the transgenic vector comprises about 5-100 V gene segments, with at least one human V gene segment, wherein the human V gene segment is placed downstream to the 5-100 V gene segments of the non-human animal. In a specific embodiment, the human V gene segment is placed immediately 5′ to a J gene segment in a rearranged configuration. In another embodiment, the humanized Ig light chain locus present in the transgenic vector comprises more than one human V gene segment.
In a still further embodiment, the humanized Ig light chain locus present in the transgenic vector comprises about 1-10 J gene segments, with at least one human J gene segment. In a specific embodiment, the humanized Ig light chain locus present in the transgenic vector comprises more than one human J gene segment.
In another embodiment, the humanized Ig light chain locus present in the transgenic vector comprises about 1-25 C region segments, with at least one human C region segment. In a specific embodiment, the humanized Ig light chain locus present in the transgenic vector comprises more than one human C gene segment.
In a still further embodiment, the humanized Ig locus present in the transgenic vector is a light chain locus of a non-human animal, and it comprises at least one V gene segment, at least one J gene segment and at least one constant (C) region gene segment, where at least one gene segment is selected from the group of human light chain V and J segments and human light chain C region segments. In a specific embodiment, the constant region gene segment is a human light chain constant region gene segment, which can, for example, be a Cλ or Cκ gene segment. In another embodiment, the humanized Ig light chain locus comprises two or more segments selected from human V and J segments and human C region segments. In a further embodiment, the humanized Ig light chain locus comprises at least one human V segment, at least one human J segment, and at least one human C region segment.
In a different aspect, the invention concerns a nucleic acid molecule comprising two or more units consisting of, from 5′ to 3′ direction, a 5′ nucleotide sequence, a human immunoglobulin sequence, and a 3′ nucleotide sequence, wherein the 5′ and 3′ nucleotide sequences are identical or different, and comprise at least about 20 contiguous nucleotides from a spacer sequence separating the coding regions in a non-primate animal immunoglobulin heavy or light chain gene, or from a consensus sequence of two or more of the spacer sequences. In a specific embodiment, the spacer sequences are selected from within SEQ ID NOS: 1 to 185 (Table 1). In another particular embodiment, the 5′ and/or 3′ nucleotide sequences in all repetitive units of the nucleic acid molecule are identical. In another particular embodiment, the repetitive units of the nucleic acid molecule comprise at least two different 5′ and/or 3′ sequences. In a further embodiment, the 5′ and 3′ nucleotide sequence are different from each other, but all 5′ and all 3′ nucleotide sequences are identical.
In a further aspect, the invention concerns a method for making a transgenic vector comprising a humanized immunoglobulin (Ig) locus capable of producing a functional repertoire of humanized antibodies in a non-human animal, comprising:
(a) obtaining a DNA fragment comprising an Ig locus or a portion thereof from the non-human animal which comprises at least one V gene segment, at least one J gene segment and at least one constant region gene segment; and
(b) integrating at least one human Ig gene segment into the DNA fragment of step (a) to produce a humanized Ig locus, wherein the human Ig gene segment flanked by nucleotide sequences comprising at least about 20 contiguous nucleotides from a spacer sequence separating the coding regions in a non-primate animal immunoglobulin heavy or light chain gene, or from a consensus sequence or two or more of such spacer sequences; wherein (i) the gene segments are juxtaposed in an unrearranged, partially rearranged or fully rearranged configuration, and (ii) the humanized Ig locus is capable of undergoing gene rearrangement, if necessary, and producing a repertoire of humanized immunoglobulins in the non-human animal.
The humanized Ig locus can be a humanized Ig heavy chain or light chain locus. In the case of a humanized Ig heavy chain locus the DNA fragment obtained in step (a) additionally comprises at least one D gene segment.
In another aspect, the invention concerns a transgenic animal comprising a humanized immunoglobulin locus described above, and methods for making such transgenic animals. In one embodiment, the transgenic animal comprises both a humanized immunoglobulin heavy chain locus and a humanized immunoglobulin light chain locus. In another embodiment, only one of the heavy and light chain loci present in the transgenic animal is humanized. In another embodiment, all of the V, D, J and C regions of at least one of the animal's immunoglobulin loci are humanized. In yet another embodiment, all of the V, D, J, and C region of the transgenic animals endogenous immunoglobulin loci are humanized.
In a further aspect, the invention concerns a B cell from the transgenic animals produced in accordance with the present invention.
In a still further aspect, the invention concerns a humanized immunoglobulin produced using a transgenic animal of the present invention, and an antibody preparation or a pharmaceutical composition comprising the humanized immunoglobulin.
“Antibodies” (Abs) and “immunoglobulins” (Igs) are glycoproteins having the same structural characteristics. While antibodies exhibit binding specificity to a specific antigen, immunoglobulins include both antibodies and other antibody-like molecules which lack antigen specificity. Polypeptides of the latter kind are, for example, produced at low levels by the lymph system and at increased levels by myelomas.
“Native antibodies and immunoglobulins” are usually heterotetrameric glycoproteins of about 150,000 daltons, composed of two identical light (L) chains and two identical heavy (H) chains. Each light chain is linked to a heavy chain by covalent disulfide bond(s), while the number of disulfide linkages varies between the heavy chains of different immunoglobulin isotypes. Each heavy and light chain also has regularly spaced intrachain disulfide bridges. Each heavy chain has at one end a variable domain (VH) followed by a number of constant domains. Each light chain has a variable domain at one end (VL) and a constant domain at its other end; the constant domain of the light chain is aligned with the first constant domain of the heavy chain, and the light chain variable domain is aligned with the variable domain of the heavy chain. Particular amino acid residues are believed to form an interface between the light- and heavy-chain variable domains (Clothia et al., J. Mol. Biol. 186:651 (1985); Novotny and Haber, Proc. Natl. Acad. Sci. U.S.A. 82:4592 (1985)).
The term “variable” refers to the fact that certain portions of the variable domains differ extensively in sequence among antibodies and are used in the binding and specificity of each particular antibody for its particular antigen. However, the variability is not evenly distributed throughout the variable domains of antibodies. It is concentrated in three segments called complementarity-determining regions (CDRs) or hypervariable regions both in the light-chain and the heavy-chain variable domains. The more highly conserved portions of variable domains are called the framework (FR). The variable domains of native heavy and light chains each comprise four FR regions, connected by three CDRs. The CDRs in each chain are held together in close proximity by the FR regions and, with the CDRs from the other chain, contribute to the formation of the antigen-binding site of antibodies (see Kabat et al., Sequences of Proteins of Immunological Interest, Fifth Edition, National Institute of Health, Bethesda, Md. (1991)). The constant domains are not involved directly in binding an antibody to an antigen, but exhibit various effector functions, such as participation of the antibody in antibody-dependent cellular toxicity.
The term “monoclonal antibody” is used to refer to an antibody molecule synthesized by a single clone of B cells.
The term “polyclonal antibody” is used to refer to a population of antibody molecules synthesized by many clones of B cells. In a specific embodiment, polyclonal antibodies recognize several epitopes.
The terms “a humanized antibody” and “a humanized immunoglobulin”, as used herein, mean an immunoglobulin molecule comprising at least a portion of a human immunoglobulin polypeptide sequence (or a polypeptide sequence encoded by a human immunoglobulin gene segment). The humanized immunoglobulin molecules of the present invention can be isolated from a transgenic non-human animal engineered to produce humanized immunoglobulin molecules. Such humanized immunoglobulin molecules are less immunogenic to primates, especially humans, relative to non-humanized immunoglobulin molecules prepared from the animal or prepared from cells derived from the animal.
The term “non-human animal” as used herein includes, but is not limited to mammals, and includes, for example, non-human primates, rabbits, pigs, birds (e.g., chickens, turkeys, ducks, geese and the like), sheep, goats, cows, horses, and rodents (e.g. mice and rats). Preferred non-human animals are those animals which create antibody diversity substantially by gene conversion and/or somatic hypermutation, e.g., rabbit, pigs, birds (e.g., chicken, turkey, duck, goose and the like), sheep, goat, and cow. Particularly preferred non-human animals are rabbit and chicken.
The term “non-primate animal” as used herein includes, but is not limited to, mammals other than primates, including those listed above.
The phrase “animals which create antibody diversity substantially by gene conversion and/or hypermutation” is used to refer to animals in which the predominant mechanism of antibody diversification is gene conversion and/or hypermutation as opposed to gene rearrangement.
The term “Ig gene segment” as used herein refers to segments of DNA encoding various portions of an Ig molecule, which are present in the germline of animals and humans, and which are brought together in B cells to form rearranged Ig genes. Thus, Ig gene segments as used herein include V gene segments, D gene segments, J gene segments and C region gene segments.
The term “human Ig gene segment” as used herein includes both naturally occurring sequences of a human Ig gene segment, degenerate forms of naturally occurring sequences of a human Ig gene segment, as well as synthetic sequences that encode a polypeptide sequence substantially identical to the polypeptide encoded by a naturally occurring sequence of a human Ig gene segment. By “substantially” is meant that the degree of amino acid sequence identity is at least about 85%-95%. In a particular embodiment, the human Ig gene segment renders the immunoglobulin molecule non-immunogenic in humans.
A specific humanized immunoglobulin molecule of the present invention contains at least a portion of a human heavy or light chain variable region polypeptide sequence. Another specific immunoglobulin molecule contains at least a portion of a human heavy or light chain variable region polypeptide sequence, and at least a portion of a human constant domain polypeptide sequence.
By “a preparation of humanized antibodies” or “a humanized antibody preparation” is meant an isolated antibody product or a purified antibody product prepared from a transgenic non-human animal (e.g., serum, milk, or egg yolk of the animal) or from cells derived from a transgenic non-human animal (e.g., a B-cell or a hybridoma cell).
A humanized antibody preparation can be a preparation of polyclonal antibodies, which includes a repertoire of humanized immunoglobulin molecules. A humanized antibody preparation can also be a preparation of a monoclonal antibody.
The terms “antibody diversity” and “antibody repertoire” are used interchangeably, and refer to the total of all antibody specificities that an organism is capable of expressing.
The term “spacer sequence” is used herein to refer to any non-coding nucleotide sequence present in an immunoglobulin heavy or light chain gene. Thus, the term specifically includes intron sequences and any other non-coding sequences separating the coding regions within the V, D, J segments and C region segments in an immunoglobulin heavy chain gene, intron sequences and any other non-coding sequences separating the coding regions within the V and J segments an C region segments in an immunoglobulin light chain gene, as well as non-coding sequence flanking regulatory elements, such as enhancers, in an immunoglobulin heavy or light chain gene. In addition, non-coding sequences between exons encoding parts of a membrane-spanning helix and heavy and light chain enhancers are specifically included.
An Ig locus having the capacity to undergo gene rearrangement and gene conversion is also referred to herein as a “functional” Ig locus, and the antibodies with a diversity generated by a functional Ig locus are also referred to herein as “functional” antibodies or a “functional” repertoire of antibodies.
Regulatory elements in immunoglobulin genes have been described by Bradley et al. (1999), Transcriptional enhancers and the evolution of the IgH locus; Lauster, R. et al., Embo J 12: 4615-23 (1993); Volgina et al., J Immunol 165:6400 (2000); Hole et al., J Immunol 146:4377 (1991).
Antibody diversification by gene conversion in chicken and rabbit has been described by Bucchini et al., Nature 326: 409-11 (1987); Knight et al., Advances in Immunology 56: 179-218 (1994); Langman et al., Res Immunol 144: 422-46 (1993). The generation of mice expressing human-mouse chimeric antibodies has been described by Pluschke et al., Journal of Immunological Methods 215: 27-37 (1998). The generation of mice expressing human-mouse chimeric antibodies with mouse derived membrane and cytoplamic tails has been described by Zou et al., Science 262: 1271-1274 (1993); Zou et al. Curr Biol 4: 1099-1103. The generation of mice expressing human immunoglobulin polypeptides has been described by Bruggemann et al. Curr Opin Biotechnol 8(4): 455-8 (1997); Lonberg et al. Int Rev Immunol 13(1):65-93 (1995); Neuberger et al., Nature 338: 350-2 (1989). Generation of transgenic mice using a BAC clone has been described by Yang et al., Nat Biotechnol 15: 859-65 (1997). The generation of cows expressing human antibodies has been described by Kuroiwa et al., Nature Biotech 20(9): 889-894 (2002).
The generation of transgenic rabbits has been described by Fan, J. et al., Pathol Int 49: 583-94 (1999); Brem et al., Mol Reprod Dev 44: 56-62 (1996). Rabbits with impaired immunoglobulin expression have been described by McCartney-Francis et al., Mol Immunol 24: 357-64 (1987); Allegrucci, et al., Eur J Immunol 21: 411-7 (1991).
The production of transgenic chicken has been described by Sherman et al., Nature Biotech 16:1050-1053 (1998); Etches et al., Methods in Molecular Biology 62: 433-450; Pain et al., Cells Tissues Organs 165(3-4): 212-9 (1999); Sang, H., “Transgenic chickens—methods and potential applications”, Trends Biotechnol 12:415 (1994); and in WO2004003157, “Gene regulation in transgenic animals using a transposon based vector”; and in WO 200075300, “Introducing a nucleic acid into an avian genome, useful for transfecting avian blastodermal cells for producing transgenic avian animals with the desired genes, by directly introducing the nucleic acid into the germinal disc of the egg”.
A gammaglobulinemic chicken have been described by Frommel et al., J Immunol 105(1): 1-6 (1970); Benedict et al., Adv Exp Med Biol 1977; 88(2): 197-205.
The cloning of animals from cells has been described by T. Wakayama et al., Nature 1998; 394:369-374; J. B. Cibelli et al., Science 280:1256-1258 (1998); J. B. Cibelli et al., Nature Biotechnology 1998; 16:642-646; A. E. Schnieke et al., Science 278: 2130-2133 (1997); K. H. Campbell et al., Nature 380: 64-66 (1996), Kuroiwa et al., Nature Genetics 2004, Jun. 6. Nuclear transfer cloning of rabbits has been described by Stice et al., Biology of Reproduction 39: 657-664 (1988), and Challah-Jacques et al., Cloning and Stem Cells 8(4):295-299 (2003).
Production of antibodies from transgenic animals is described in U.S. Pat. No. 5,814,318, No. 5,545,807 and No. 5,570,429. Homologous recombination for chimeric mammalian hosts is exemplified in U.S. Pat. No. 5,416,260. A method for introducing DNA into an embryo is described in U.S. Pat. No. 5,567,607. Maintenance and expansion of embryonic stem cells is described in U.S. Pat. No. 5,453,357.
The mechanisms involved in the diversification of the antibody repertoire in pigs, sheep and cows are reviewed in Butler, J. E. (1998), “Immunoglobulin diversity, B-cell and antibody repertoire development in large farm animals”, Rev Sci Tech 17:43. Antibody diversification in sheep is described in Reynaud, C. A., C. Garcia, W. R. Hein, and J. C. Weill (1995), “Hypermutation generating the sheep immunoglobulin repertoire is an antigen-independent process”, Cell 80:115; and Dufour, V., S. Malinge, and F. Nau. (1996), “The sheep Ig variable region repertoire consists of a single VH family,” J Immunol 156:2163.
Immunoglobulin heavy and light chain genes comprise several segments encoded by individual genes and separated by intron sequences. Thus genes for the human immunoglobulin heavy chain are found on chromosome 14. The variable region of the heavy chain (VH) comprises three gene segments: V, D and J segments, followed by multiple genes coding for the C region. The V region is separated from the C region by a large spacer, and the individual genes encoding the V D and J segments are also separated by spacers.
There are two types of immunoglobulin light chains: κ and λ. Genes for the human κ light chain are found on chromosome 2 and genes for the human λ light chain are found on chromosome 22. The variable region of antibody light chains includes a V segment and a J segment, encoded by separate gene segments. In the germline configuration of the κ light chain gene, there are approximately 100-200 V region genes in linear arrangement, each gene having its own leader sequence, followed by approximately 5 J gene segments, and C region gene segment. All V regions are separated by introns, and there are introns separating the V, J and C region gene segments as well.
The immune system's capacity to protect against infection rests in a genetic machinery specialized to create a diverse repertoire of antibodies. Antibody-coding genes in B cells are assembled in a manner that allows to countless combinations of binding sites in the variable (V) region. It is estimated that more than 1012 possible binding structures arise from such mechanisms. In all animals, including humans, the antibody-making process begins by recombining variable (V), diversity (D) and joining (J) segments of the immunoglobulin (Ig) locus. Following this step, depending on the animal species, two general mechanisms are used to produce the diverse binding structures of antibodies.
In some animals, such as human and mouse, there are multiple copies of V, D and J gene segments on the immunoglobulin heavy chain locus, and multiple copies of V and J gene segments on the immunoglobulin light chain locus. Antibody diversity in these animals is generated primarily by gene rearrangement, i.e., different combinations of gene segments to form rearranged heavy chain variable region and light chain variable region. In other animals (e.g., rabbit, birds, e.g., chicken, goose, and duck, sheep, goat, and cow), however, gene rearrangement plays a smaller role in the generation of antibody diversity. For example, in rabbit, only a very limited number of the V gene segments, most often the V gene segments at the 3′ end of the V-region, is used in gene rearrangement to form a contiguous VDJ segment. In chicken, only one V gene segment (the one adjacent to the D region, or “the 3′ proximal V gene segment”), one D segment and one J segment are used in the heavy chain rearrangement; and only one V gene segment (the 3′ proximal V segment) and one J segment are used in the light chain rearrangement. Thus, in these animals, there is little diversity among initially rearranged variable region sequences resulting from junctional diversification. Further diversification of the rearranged Ig genes is achieved by gene conversion, a process in which short sequences derived from the upstream V gene segments replace short sequences within the V gene segment in the rearranged Ig gene. Additional diversification of antibody sequences may be generated by hypermutation.
Immunoglobulins (antibodies) belong into five classes (IgG, IgM, IgA, IgE, and IgD, each with different biological roles in immune defense. The most abundant in the blood and potent in response to infection is the IgG class. Within the human IgG class, there are four sub-classes (IgG1, IgG2, IgG3 and IgG4 isotypes) determined by the structure of the heavy chain constant regions that comprise the Fc domain. The F(ab) domains of antibodies bind to specific sequences (epitopes) on antigens, while the Fc domain of antibodies recruits and activates other components of the immune system in order to eliminate the antigens.
Antibodies have been used successfully as therapeutics since the 1890s when it was found that polyclonal antiserum taken from animals could treat life-threatening infections in humans. A significant advance in antibody research occurred with the development of methods for the recombinant production of antibodies, followed by the development of antibody humanization techniques and method for making fully human monoclonal antibodies in non-human animals.
As a result, chimeric, humanized and human monoclonal antibodies have recently emerged as an important class of pharmaceutical products. While monoclonal antibody-based drugs are very effective in treating diseases when blocking a particular target (e.g. receptor or ligand) certain devastating diseases, such as cancer and infections with virulent pathogens, may be difficult to treat due to their complexity, multifactoral etiology and adaptivity. Monoclonal antibodies address singularly defined targets that change, evolve and mutate during the spread of diseases throughout a population or within an individual. Such adaptive evolution is the bane of mono-specific drugs (e.g. monoclonal antibodies), which are quickly circumvented by resistant strains. Examples abound of bacterial and viral resistance to high-potency antibiotics, and malignant cancers that develop resistance to standard anticancer drugs, such as monoclonal antibody therapies.
In contrast, polyclonal antibodies have the ability to bind and eliminate a plurality of evolving targets linked with complex diseases. By binding multiple antigens, polyclonal antibodies saturate the target and retain activity even in the event of antigen mutation. Following this, through a cascade of signals, polyclonal antibodies induce a potent immune response to eliminate the target antigen, pathogen or cell. These properties make polyclonal antibodies ideal for treating infectious diseases and cancer.
So far, the use of polyclonal antibodies has been severely limited by either supply problems or unwanted reactions to non-human proteins.
The present invention provides a new humanization approach, based on selective humanization the immunoglobulin-coding elements of the immunoglobulin (Ig) translocus. The creation of such human-animal translocus allows for the creation of transgenic animals that express diversified, high-affinity humanized (polyclonal) antibodies in high yields.
As a first step, the genomic loci for non-human, including non-primate, immunoglobulin heavy and light chains are identified and sequenced. For example, as part of the present invention, genomic sequences for rabbit and chicken immunoglobulin heavy and light chains were determined, and are shown in
Analysis of the rabbit Ig heavy chain genomic locus has shown that the immunoglobulin heavy chain variable region (Vh) contains numerous genes, including functional genes and non-functional pseudogenes. Alignment of 18 Vh genes has revealed a high degree (80-90%) sequence identity among rabbit heavy chain variable region gene sequences (Vh1-Vh18). The rabbit heavy chain variable region genes have been found to share highest homology with the Vh3 group of the human heavy chain variable region genes. Specifically, sequence comparison of the rabbit Vh1-a2 gene with the human Vh3-23 sequences has revealed 72.8% sequence identity.
In addition, the non-coding (e.g. intron) sequences separating the rabbit heavy chain variable region gene sequences were analyzed.
Similar findings were made by analysis of rabbit immunoglobulin light chain variable region genomic sequences. In particular, analysis of the rabbit immunoglobulin light chain locus has shown that the light chain variable region (V1) region contains numerous gene segments, which show a high degree (80-90% sequence identity). It has further been found that the rabbit light chain variable region (Vκ) exhibits high homology with the Vκ1 group of the human light chain variable region gene sequences. Most Vκ sequences have been found to be functional and highly conserved. Unlike in the rabbit heavy chain variable region genes, in the rabbit light chain variable region genes the intron sequences have been found to be heterogeneous.
Similar studies with chicken immunoglobulin heavy and light chain genomic sequences provide analogous results.
In one aspect, the present invention provides spacer sequences, which separate the coding regions in a non-primate animal heavy or light chain gene. In one embodiment, the present invention provides spacer sequences from the heavy and light chain genes of animals which create antibody diversity substantially by gene conversion, including, for example, rabbit and chicken. Such spacer sequences are then used to flank human immunoglobulin heavy or light chain gene segments used in the process of creating a humanized immunoglobulin locus.
The spacer sequences typically comprise at least about 20 nucleotides, or at least about 30 nucleotides, or at least about 40 nucleotides, or at least about 50 nucleotides, and typically are between about 20 and about 10000 nucleotides in length. The spacer sequences may contain a contiguous stretch of nucleotides of appropriate length from a naturally occurring intron sequence in a non-human (e.g. non-primate) animal, or may include an artificial sequence, which may, for example, be a consensus sequence of two or more naturally occurring intron sequences.
The spacer sequences may comprise at least about 20 (30, 40, 50, etc. up to 1000 in 10-nucleotide increments) contiguous nucleotides from a sequence selected from the group consisting of SEQ ID NOS 1 to 185 (Table 1), or from a consensus sequence of two or more of such sequences. It is possible, but not necessary, to separate human heavy or light chain sequences (e.g. V, D, J, C region sequences) used for humanization by spacer sequences that separate the corresponding regions within the genomic sequence of the non-human (non-primate) animal the immunoglobulin of which is humanized.
In general, the humanization of an immunoglobulin (Ig) locus in a non-human animal involves the integration of one or more human Ig gene segments into the animal's genome to create humanized immunoglobulin loci. Thus, creation of a humanized Ig heavy chain locus involves the integration of one or more V and/or D and/or J segments, and/or C region segments into the animal's genome. Similarly, the creation of a humanized Ig light chain locus involves the integration of one or more V and/or J segments, and/or C region segments into the animal's genome.
Depending upon the approach used, the human Ig gene segment(s) can be integrated at the chromosomal location where the endogenous Ig locus of the animal ordinarily resides, or at a different locus of the animal. Regardless of the chromosomal location, the humanized Ig locus of the present invention has the capacity to undergo gene rearrangement and gene conversion and hypermutation in the non-human animal, thereby producing a diversified repertoire of humanized Ig molecules. An Ig locus having the capacity to undergo gene rearrangement and gene conversion is also referred to as a “functional” Ig locus and the antibodies with a diversity generated by a functional Ig locus are also referred to as “functional” antibodies or a “functional” repertoire of antibody molecules.
In a further aspect, the invention provides nucleic acid molecules comprising a human Ig gene segment, flanked by nucleotide sequences which comprise at least bout 20 contiguous nucleotides from a spacer sequence separating the coding regions in a non-primate animal Ig heavy or light chain gene, or from a consensus sequence of two or more of such spacer sequences. The flanking sequences just as the spacer sequence-derived sections within the flanking sequences can be identical or different. The contiguous nucleotides derived from a spacer sequence or from a consensus sequence of two or more spacer sequences can be fused directly to the human Ig gene segment. Alternatively, there might be an intervening sequence between the human Ig gene segment and at least one of the spacer-originating nucleotide sequences. Thus, for example, a flanking sequence at the 5′ end of a human V gene segment may include a promoter region, which is linked directly to the human V gene segment, and separates it from the spacer-sequence derived nucleotide stretch of at least 20 nucleotides.
In yet another aspect, the invention concerns a humanized Ig heavy chain locus in which human heavy chain V, D and/or J gene segments and/or C region segments are present in the same configuration as in the original non-human animal immunoglobulin gene, and separated by sequences including at least about 20 contiguous nucleotides from an intron sequence separating the coding regions in a non-primate animal Ig heavy or light chain gene. In another embodiment, the present invention provides a humanized light chain locus in which human light chain C region segments and/or J gene segments and/or V region segments are separated by non-human animal (e.g. non-primate) intron sequences in the same configuration as in the original non-human animal immunoglobulin gene. In a particular embodiment, the spacer sequences are designed based on non-coding, e.g. intron sequences of the non-human (non-primate) animal. In one embodiment, the spacers may retain the appropriate non-coding sequences from the non-human (non-primate) animal. Alternatively, in order to simplify the construct, a consensus sequence, designed based upon the highly homologous non-coding (intron) sequences may be designed, and used as a uniform spacer sequence for the preparation of multiple human heavy or light chain gene segments.
The invention specifically provides isolated nucleic acid sequences and vectors useful in the construction of humanized immunoglobulin loci.
In one embodiment, DNA fragments containing an Ig locus to be humanized are isolated from animals which generate antibody diversity by gene conversion, e.g., rabbit and chicken. Such large DNA fragments can be isolated by screening a library of plasmids, cosmids, yeast artificial chromosomes (YACs) or bacterial artificial chromosomes (BACs), and the like, prepared from the genomic DNA of the non-human, e.g. non-primate animal. An entire animal C-region can be contained in one plasmid or cosmid clone which is subsequently subjected to humanization. YAC clones can carry DNA fragments of up to 2 megabases, thus an entire animal heavy chain locus or a large portion thereof can be isolated in one YAC clone, or reconstructed to be contained in one YAC clone. BAC clones are capable of carrying DNA fragments of smaller sizes (about 150-450 kb). However, multiple BAC clones containing overlapping fragments of an Ig locus can be separately humanized and subsequently injected together into an animal recipient cell, wherein the overlapping fragments recombine in the recipient animal cell to generate a continuous Ig locus.
Human Ig gene segments can be integrated into the Ig locus on a vector (e.g., a BAC clone) by a variety of methods, including ligation of DNA fragments, or insertion of DNA fragments by homologous recombination. Integration of the human Ig gene segments is done in such a way that the human Ig gene segment is operably linked to the host animal sequence in the transgene to produce a functional humanized Ig locus, i.e., an Ig locus capable of gene rearrangement and gene conversion and hypermutation which lead to the production of a diversified repertoire of humanized antibodies.
In one embodiment, human Ig gene segments can be integrated into the Ig locus by homologous recombination. Homologous recombination can be performed in bacteria, yeast and other cells with a high frequency of homologous recombination events. For example, a yeast cell is transformed with a YAC containing an animal's Ig locus or a large portion thereof. Subsequently, such yeast cell is further transformed with a recombination vector as described hereinabove, which carries a human Ig gene segment linked to a 5′ flanking sequence and a 3′ flanking sequence. The 5′ and the 3′ flanking sequences in the recombination vector are homologous to those flanking sequences of the animal Ig gene segment on the YAC. As a result of a homologous recombination, the animal Ig gene segment on the YAC is replaced with the human Ig gene segment. Alternatively, a bacterial cell such as E. coli is transformed with a BAC containing an animal's Ig locus or a large portion thereof. Such bacterial cell is further transformed with a recombination vector which carries a human Ig gene segment linked to a 5′ flanking sequence and a 3′ flanking sequence. The 5′ and the 3′ flanking sequences in the recombination vector mediate homologous recombination and exchange between the human Ig gene segment on the recombination vector and the animal Ig gene segment on the BAC. Humanized YACs and BACs can be readily isolated from the cells and used in making transgenic animals.
In a further aspect of the present invention, methods of making transgenic animals capable of producing humanized immunoglobulins are provided.
According to the present invention, a transgenic animal capable of making humanized immunoglobulins are made by introducing into a recipient cell or cells of an animal one or more of the transgenic vectors described herein above which carry a humanized Ig locus, and deriving an animal from the genetically modified recipient cell or cells.
The recipient cells may, for example, be from non-human animals which generate antibody diversity by gene conversion and/or hypermutation, e.g., bird (such as chicken), rabbit, cows and the like. In such animals, the 3′proximal V gene segment is preferentially used for the production of immunoglobulins. Integration of a human V gene segment into the Ig locus on the transgene vector, either by replacing the 3′proximal V gene segment of the animal or by being placed in close proximity of the 3′proximal V gene segment, results in expression of human V region polypeptide sequences in the majority of immunoglobulins. Alternatively, a rearranged human V(D)J segment may be inserted into the J locus of the immunoglobulin locus on the transgene vector.
The transgenic vectors containing a humanized Ig locus is introduced into the recipient cell or cells and then integrated into the genome of the recipient cell or cells by random integration or by targeted integration.
For random integration, a transgenic vector containing a humanized Ig locus can be introduced into an animal recipient cell by standard transgenic technology. For example, a transgenic vector can be directly injected into the pronucleus of a fertilized oocyte. A transgenic vector can also be introduced by co-incubation of sperm with the transgenic vector before fertilization of the oocyte. Transgenic animals can be developed from fertilized oocytes. Another way to introduce a transgenic vector is by transfecting embryonic stem cells and subsequently injecting the genetically modified embryonic stem cells into developing embryos. Alternatively, a transgenic vector (naked or in combination with facilitating reagents) can be directly injected into a developing embryo. Ultimately, chimeric transgenic animals are produced from the embryos which contain the humanized Ig transgene integrated in the genome of at least some somatic cells of the transgenic animal.
In a particular embodiment, a transgene containing a humanized Ig locus is randomly integrated into the genome of recipient cells (such as fertilized oocyte or developing embryos) derived from animal strains with an impaired expression of endogenous immunoglobulin genes. The use of such animal strains permits preferential expression of immunoglobulin molecules from the humanized transgenic Ig locus. Examples for such animals include the Alicia and Basilea rabbit strains, as well as Agammaglobinemic chicken strain, as well as immunoglobulin knock-out mice. Alternatively, transgenic animals with humanized immunoglobulin transgenes or loci can be mated with animal strains with impaired expression of endogenous immunoglobulins. Offspring homozygous for an impaired endogenous Ig locus and a humanized transgenic Ig locus can be obtained.
For targeted integration, a transgenic vector can be introduced into appropriate animal recipient cells such as embryonic stem cells or already differentiated somatic cells. Afterwards, cells in which the transgene has integrated into the animal genome and has replaced the corresponding endogenous Ig locus by homologous recombination can be selected by standard methods See for example, Kuroiwa et al, Nature Genetics 2004, Jun. 6. The selected cells may then be fused with enucleated nuclear transfer unit cells, e.g. oocytes or embryonic stem cells, cells which are totipotent and capable of forming a functional neonate. Fusion is performed in accordance with conventional techniques which are well established. Enucleation of oocytes and nuclear transfer can also be performed by microsurgery using injection pipettes. (See, for example, Wakayama et al., Nature (1998) 394:369). The resulting egg cells are then cultivated in an appropriate medium, and transferred into synchronized recipients for generating transgenic animals. Alternatively, the selected genetically modified cells can be injected into developing embryos which are subsequently developed into chimeric animals.
Further, according to the present invention, a transgenic animal capable of producing humanized immunoglobulins can also be made by introducing into a recipient cell or cells, one or more of the recombination vectors described herein above, which carry a human Ig gene segment, linked to 5′ and 3′ flanking sequences that are homologous to the flanking sequences of the endogenous Ig gene segment, selecting cells in which the endogenous Ig gene segment is replaced by the human Ig gene segment by homologous recombination, and deriving an animal from the selected genetically modified recipient cell or cells.
Similar to the target insertion of a transgenic vector, cells appropriate for use as recipient cells in this approach include embryonic stem cells or already differentiated somatic cells. A recombination vector carrying a human Ig gene segment can be introduced into such recipient cells by any feasible means, e.g., transfection. Afterwards, cells in which the human Ig gene segment has replaced the corresponding endogenous Ig gene segment by homologous recombination, can be selected by standard methods. These genetically modified cells can serve as nuclei donor cells in a nuclear transfer procedure for cloning a transgenic animal. Alternatively, the selected genetically modified embryonic stem cells can be injected into developing embryos which can be subsequently developed into chimeric animals.
Transgenic animals produced by any of the foregoing methods form another embodiment of the present invention. The transgenic animals have at least one, i.e., one or more, humanized Ig loci in the genome, from which a functional repertoire of humanized antibodies is produced.
In a specific embodiment, the present invention provides transgenic rabbits having one or more humanized Ig loci in the genome. The transgenic rabbits of the present invention are capable of rearranging and gene converting the humanized Ig loci, and expressing a functional repertoire of humanized antibodies.
In another specific embodiment, the present invention provides transgenic chickens having one or more humanized Ig loci in the genome. The transgenic chickens of the present invention are capable of rearranging and gene converting the humanized Ig loci, and expressing a functional repertoire of humanized antibodies In another specific embodiment, the present invention provides transgenic mice with one or more humanized V regions in the genome. The humanized V region comprises at least two human V gene segments flanked by non-human spacer sequences. The transgenic mice are capable of rearranging the human V elements and expressing a functional repertoire of antibodies.
Once a transgenic non-human animal capable of producing diversified humanized immunoglobulin molecules is made, humanized immunoglobulins and humanized antibody preparations against an antigen can be readily obtained by immunizing the animal with the antigen. A variety of antigens can be used to immunize a transgenic host animal. Such antigens include, without limitation, microorganisms, e.g. viruses and unicellular organisms (such as bacteria and fungi), alive, attenuated or dead, fragments of the microorganisms, or antigenic molecules isolated from the microorganisms.
Exemplary bacterial antigens for use in immunizing an animal include purified antigens from Staphylococcus aureus such as capsular polysaccharides type 5 and 8, recombinant versions of virulence factors such as alpha-toxin, adhesin binding proteins, collagen binding proteins, and fibronectin binding proteins. Exemplary bacterial antigens also include an attenuated version of S. aureus, Pseudomonas aeruginosa, enterococcus, enterobacter, and Klebsiella pneumoniae, or culture supernatant from these bacteria cells. Other bacterial antigens which can be used in immunization include purified lipopolysaccharide (LPS), capsular antigens, capsular polysaccharides and/or recombinant versions of the outer membrane proteins, fibronectin binding proteins, endotoxin, and exotoxin from Pseudomonas aeruginosa, enterococcus, enterobacter, and Klebsiella pneumoniae.
Exemplary antigens for the generation of antibodies against fungi include attenuated version of fungi or outer membrane proteins thereof, which fungi include, but are not limited to, Candida albicans, Candida parapsilosis, Candida tropicalis, and Cryptococcus neoformans.
Exemplary antigens for use in immunization in order to generate antibodies against viruses include the envelop proteins and attenuated versions of viruses which include, but are not limited to respiratory synctial virus (RSV) (particularly the F-Protein), Hepatitis C virus (HCV), Hepatits B virus (HBV), cytomegalovirus (CMV), EBV, and HSV.
Therapeutic antibodies can be generated for the treatment of cancer by immunizing transgenic animals with isolated tumor cells or tumor cell lines; tumor-associated antigens which include, but are not limited to, Her-2-neu antigen (antibodies against which are useful for the treatment of breast cancer); CD19, CD20, CD22 and CD53 antigens (antibodies against which are useful for the treatment of B cell lymphomas), (3) prostate specific membrane antigen (PMSA) (antibodies against which are useful for the treatment of prostate cancer), and 17-1A molecule (antibodies against which are useful for the treatment of colon cancer).
The antigens can be administered to a transgenic host animal in any convenient manner, with or without an adjuvant, and can be administered in accordance with a predetermined schedule.
After immunization, serum or milk from the immunized transgenic animals can be fractionated for the purification of pharmaceutical grade polyclonal antibodies specific for the antigen. In the case of transgenic birds, antibodies can also be made by fractionating egg yolks. A concentrated, purified immunoglobulin fraction may be obtained by chromatography (affinity, ionic exchange, gel filtration, etc.), selective precipitation with salts such as ammonium sulfate, organic solvents such as ethanol, or polymers such as polyethyleneglycol.
For making a monoclonal antibody, spleen cells are isolated from the immunized transgenic animal and used either in cell fusion with transformed cell lines for the production of hybridomas, or cDNAs encoding antibodies are cloned by standard molecular biology techniques and expressed in transfected cells. The procedures for making monoclonal antibodies are well established in the art. See, e.g., European Patent Application 0 583 980 A1 (“Method For Generating Monoclonal Antibodies From Rabbits”), U.S. Pat. No. 4,977,081 (“Stable Rabbit-Mouse Hybridomas And Secretion Products Thereof”), WO 97/16537 (“Stable Chicken B-cell Line And Method of Use Thereof”), and EP 0 491 057 B1 (“Hybridoma Which Produces Avian Specific Immunoglobulin G”), the disclosures of which are incorporated herein by reference. In vitro production of monoclonal antibodies from cloned cDNA molecules has been described by Andris-Widhopf et al., “Methods for the generation of chicken monoclonal antibody fragments by phage display”, J Immunol Methods 242:159 (2000), and by Burton, D. R., “Phage display”, Immunotechnology 1:87 (1995), the disclosures of which are incorporated herein by reference.
Cells derived from the transgenic animals of the present invention, such as B cells or cell lines established from a transgenic animal immunized against an antigen, are also part of the present invention.
In a further aspect of the present invention, methods are provided for treating a disease in a primate, in particular, a human subject, by administering a purified humanized antibody composition, preferably, a humanized polyclonal antibody composition, desirable for treating such disease.
In another aspect of the present invention, purified monoclonal or polyclonal antibodies are admixed with an appropriate pharmaceutical carrier suitable for administration in primates especially humans, to provide pharmaceutical compositions. Pharmaceutically acceptable carriers which can be employed in the present pharmaceutical compositions can be any and all solvents, dispersion media, isotonic agents and the like. Except insofar as any conventional media, agent, diluent or carrier is detrimental to the recipient or to the therapeutic effectiveness of the antibodies contained therein, its use in the pharmaceutical compositions of the present invention is appropriate. The carrier can be liquid, semi-solid, e.g. pastes, or solid carriers. Examples of carriers include oils, water, saline solutions, alcohol, sugar, gel, lipids, liposomes, resins, porous matrices, binders, fillers, coatings, preservatives and the like, or combinations thereof.
The humanized polyclonal antibody compositions used for administration are generally characterized by containing a polyclonal antibody population, having immunoglobulin concentrations from 0.1 to 100 mg/ml, more usually from 1 to 10 mg/ml. The antibody composition may contain immunoglobulins of various isotypes. Alternatively, the antibody composition may contain antibodies of only one isotype, or a number of selected isotypes.
In most instances the antibody composition consists of unmodified immunoglobulins, i.e., humanized antibodies prepared from the animal without additional modification, e.g., by chemicals or enzymes. Alternatively, the immunoglobulin fraction may be subject to treatment such as enzymatic digestion (e.g. with pepsin, papain, plasmin, glycosidases, nucleases, etc.), heating, etc, and/or further fractionated.
The antibody compositions generally are administered into the vascular system, conveniently intravenously by injection or infusion via a catheter implanted into an appropriate vein. The antibody composition is administered at an appropriate rate, generally ranging from about 10 minutes to about 24 hours, more commonly from about 30 minutes to about 6 hours, in accordance with the rate at which the liquid can be accepted by the patient. Administration of the effective dosage may occur in a single infusion or in a series of infusions. Repeated infusions may be administered once a day, once a week once a month, or once every three months, depending on the half-life of the antibody preparation and the clinical indication. For applications on epithelial surfaces the antibody compositions are applied to the surface in need of treatment in an amount sufficient to provide the intended end result, and can be repeated as needed. In addition, antibodies can, for example, be administered as an intramuscular bolus injection, which may, but does not have to, be followed by continuous administration, e.g. by infusion.
The antibody compositions can be used to bind and neutralize antigenic entities in human body tissues that cause disease or that elicit undesired or abnormal immune responses. An “antigenic entity” is herein defined to encompass any soluble or cell-surface bound molecules including proteins, as well as cells or infectious disease-causing organisms or agents that are at least capable of binding to an antibody and preferably are also capable of stimulating an immune response.
Administration of an antibody composition against an infectious agent as a monotherapy or in combination with chemotherapy results in elimination of infectious particles. A single administration of antibodies decreases the number of infectious particles generally 10 to 100 fold, more commonly more than 1000-fold. Similarly, antibody therapy in patients with a malignant disease employed as a monotherapy or in combination with chemotherapy reduces the number of malignant cells generally 10 to 100 fold, or more than 1000-fold. Therapy may be repeated over an extended amount of time to assure the complete elimination of infectious particles, malignant cells, etc. In some instances, therapy with antibody preparations will be continued for extended periods of time in the absence of detectable amounts of infectious particles or undesirable cells. Similarly, the use of antibody therapy for the modulation of immune responses may consist of single or multiple administrations of therapeutic antibodies. Therapy may be continued for extended periods of time in the absence of any disease symptoms.
The subject treatment may be employed in conjunction with chemotherapy at dosages sufficient to inhibit infectious disease or malignancies. In autoimmune disease patients or transplant recipients, antibody therapy may be employed in conjunction with immunosuppressive therapy at dosages sufficient to inhibit immune reactions. The invention is further illustrated, but by no means limited, by the following examples.
High molecular weight DNA was isolated from a2b5 male rabbits. The rabbits were euthanized, spleen and kidneys were removed and rinsed in ice-cold PBS. Fat and connecting tissues were removed and processed separately. The organs were cut into pieces and homogenized in a pre-cooled Dounce homogenizer. The supernatant was transferred into cooled 50 ml falcon tubes, mixed with cold PBS and large tissue debris was allowed to sink to the bottom for 2 minutes. Cells in the supernatant were pelleted at 200 g for 10 min at 4° C., washed once with PBS, resuspended in 1 ml PBS and counted. Sets of 5×106, 5×107 and 5×108 cells were embedded in agarose plugs using the CHEF Mammalian Genomic DNA Plug Kit (BIORAD) To optimize conditions for partial digestion with HindIII, plugs were cut into 5 equal pieces and digested with 1 to 10 units of HindIII for various times and temperatures. Best results were obtained with 2 units HindIII at 4° C. for 3 hrs or 37° C. for 25 min. Digested DNA was double size fractioned on a Pulse Field Gel Electrophoresis (PFGE) apparatus using the following parameters: 6 hr backwards, 15 s switch times; 6 hr forwards, 15 s switch times; 20 hr forwards, 90 s switch times; 200V 14° C. The area of the gel with the desired size of partial digested DNA was cut and DNA was isolated using gelase. 11 ng of insert was ligated with 1 ng of HindIII digested pBELOBAC 11 and electroporated into DH10B cells. 1% of the resulting colonies was sized using NotI and revealed an average insert size of 124 kb. 1×105 clones were spotted on Nylon filters and screened by hybridization with specific probes.
Probes for screening were amplified by PCR using genomic DNA from rabbits, cloned into pBlueScript, and verified by sequencing. Primer pairs (SEQ ID NO: 193-208, Table 2) were designed according to published sequences. Several BACs representing rabbit heavy and light chain immunoglobulin loci were isolated and mapped (
BAC and fosmid clones containing rabbit immunoglobulin heavy chain locus sequences were isolated from genomic DNA libraries using probes specific for the constant, variable, and joining gene segments or the 3′ enhancer region. Isolated BACs (
Selected immunoglobulin coding sequences were exchanged with corresponding human counterparts by homologous recombination in E. Coli by ET cloning (E-Chiang Lee et al., Genomics 73, 56-65 (2001); Daiguan Yu et al., PNAS 97, 5978-5983 (2000); Muyrers et al., Nucleic Acids Research 27, 1555-1557 (1999); Zhang et al., Nature Biotechnology 18, 1314-1317 (2000)).
Alternatively, DNA fragments were recombined by ligation in vitro and subsequent transformation of E. coli. BACs and/or Fos15B or parts thereof were combined by in vitro ligation and transformation, ET cloning, or by Cre recombinase mediated integration.
For ET cloning, vectors containing target sequence were transformed into a streptomycin resistant E. coli strain containing the inducible lambda phage recombination enzymes Redα, Redβ and γ. These recombination proteins were expressed either from a co-transfected plasmid (DH10B E. coli cells with plasmid pSC101) or from a genomic integrated lambda prophage (DY380 E. coli strain). The ET cloning procedure encompassed two homologous recombination steps.
In a first step the target locus was replaced by a selection-counter selection cassette (e.g. neo-rpsL which confers resistance to neomycin (neo) and sensitivity to streptomycin (rpsL)). After isolation of neo-resistant colonies, insertion of the selection cassette by homologous recombination was confirmed by restriction enzyme analysis and partial sequencing.
In a second step, the rpsL-neo selection cassette was exchanged with a new sequence. Streptomycin resistant clones were analyzed by restriction analysis and sequencing. Fragments used for the ET cloning procedure had flanking sequences of 20 to 50 bp length, which were identical to target sequences. Sequences used for ligation had appropriate restriction enzyme sites at their 3′ and 5′ ends. These sites were either naturally occurring sites or they were introduced by PCR using primers containing appropriate sites.
Alternatively, sequences were generated synthetically.
A humanized heavy chain was constructed by replacement of rabbit JH, Cμ in BAC 219D23 and Cγ in BAC 27N5 with their corresponding human counterparts by ET cloning. Human sequences used for the ET cloning procedures were amplified by PCR from human genomic DNA.
Human Cμ, Cγ and JH gene segments was amplified using primers (SEQ ID Nos: 209-214, Table 2) with 50 bp homologies to rabbit target sequences.
After ligation of BAC clone 225P18 with clone 219D23 and BAC 27N5 with Fosmid 15B, the ligated constructs were transformation into E. coli and connected by Cre recombinase mediated insertion. This resulted in a functional locus consisting of 18 rabbit variable genes, rabbit D region, human J region, human Cμ, human Cγ, rabbit Cϵ, rabbit Cα4 and the 3′enhancer element.
For the generation of transgenic animals the humanized BAC clones were coinjected either separately as three overlapping BACs (225P18 and 219D23 and BAC 27N5) or two overlapping combined BACs (225P18-219D23 and BAC 27N5-Fosmid 15B) or as one BAC (225P18-219D23-27N5-Fosmid 15B). Founder animals with transgenes were identified by PCR.
Four fragments denoted Unit1, Unit2, Unit3, and Unit 4 (
Unit 3 had in addition to the afore mentioned upstream flanks an Flp recombinase recognition target (FRT) sequence, followed by a Sglf I restriction endonuclease recognition sequence preceding the already mentioned Asc I site.
Unit 4 had the human VH3-23 gene 5′ flanked by the rabbit spacer I1-2, a lox66 Cre recombinase target sequence and an AscI endonuclease recognition sequence, and 3′ flanked by IV-C (5′ half) rabbit spacer sequence followed by a MluI endonuclease recognition sequence.
A gentamycin selection cassette was PCR-amplified, using primers SEQ ID NOs 215 and 216 (Table 2) containing AscI and FseI sites and ligated into a pGEM vector with a modified cloning site including AscI, FseI, and MluI endonuclease recognition sites (pGEM.Genta modified by PCR using SEQ ID NOs 217 and 218, Table 2).
Units 1, 2 and 3 were cloned into pGEM.Genta (Promega) vectors.
Unit 4 was sub-cloned into a customized pBELOBAC11 (NEB) vector linearized with Hind III, and PCR-amplified. The forward primer (SEQ ID NO: 219, Table 2) had restriction sites for HindIII, PacI and AatII, and the reverse primer (SEQ ID NO: 220) sites for Bam HI, MluI and AscI. The primers were designed in such a way that the pBELOBAC11 Chloramphenicol selection cassette was deleted. Furthermore, a Neomycin selection cassette was PCR-amplified with primers SEQ ID NOs 221 and 222 (Table 2) carrying Bam HI and Hind III restriction sites, and ligated to the modified pBELOBAC11 vector (pBB11.1).
Units 1-4 were assembled by cre-mediated recombination as described (Mejia et al, Genomics 70(2) 165-70 (2000)). First Unit 1 was cloned into the customized pgem.Genta vector, digested with Fse I and subsequently recircularized by ligation. This vectorless construct was transformed into E. coli containing pBB11.1.Unit4 and p706-Cre plasmid. Following recombination of Unit 1 with PBB11.1 unit 4, positive clones (Unit4/1) were selected on kanamycin and gentamycin containing media. Clones were characterized by restriction analyses using various enzymes.
For recombination of Unit 2, the Unit4/1 insert was excised by double digestion with AscI and PacI, and cloned into pBELOBAC11 with a modified linker (pBB11.2: modified by PCR using primers SEQ ID NOs 223 and 224, Table 2).
pBELOBAC11 was linearized with HindIII and PCR-amplified with a forward primer encoding PacI and AatII endonuclease recognition sites and a reverse primer encoding MluI and NotI endonuclease recognition sites and a lox66 Cre recombinase target site. For ligation with Unit1/4 the pBB11.2 vector was opened with MluI and PacI. pGEM.Genta.Unit2 was converted into a circular vectorless construct as described for pGEM.Genta.Unit1 and connected with pBB11.2.Unit4/1 by in vivo Cre mediated recombination. Subsequently, the resulting construct pBB11.2.Unit4/1/2 is prepared for Cre mediated recombination with Unit 3 by replacing the wild type loxp site with a lox66 target site by ET-cloning (Muyrers et al., Nucleic Acids Research 27, 1555-1557 (1999); Muyrers et at Trends Biochem. Sci. 26(5):325-31 (2001)). A chloramphenicol selection cassette was amplified by PCR with primers (SEQ ID NOs 225 and 226, Table 2) containing 50 bp sequences homologous to the BAC target sequence. The reverse primer included a lox66 site. The gel-purified PCR product was transformed into cells carrying the target BAC as well as the pSC101 plasmid, required for homologous recombination. Positive clones were selected with chloramphenicol and confirmed by restriction analysis and sequencing. pGEM.Genta.Unit 3 was prepared for in vivo recombination as described above for Unit1 and 2 and transformed into cells carrying the receptor BAC, as well as the p706-Cre plasmid. Positive clones pBB11.2.Unit4/1/2/3 were selected with gentamycin and confirmed by restriction analysis. pBB11.2.Unit4/1/2/3 was further modified by ET-cloning to generate a lox 71 target site. Subsequently, pBB11.2.Unit4/1/2/3 was connected to fragments from BACs 219D23, 27N5 and Fos15B.
Human VH elements were amplified using genomic DNA (ClonTech) and primers SEQ ID NOs 227-248 (Table 2). PCR products were analyzed by gel-electrophoresis and gel purified using the GENECLEAN kit (Q-Biogen). Subsequently, amplification products were sub-cloned into Zero-Blunt TOPO™ (Invitrogen), according to the manufacturer's instructions. The sequences of all amplified V elements were confirmed. For the construction of the humanized V region, V elements were amplified using plasmid DNA as template and primers SEQ ID NOs 249-270 (Table 2). Forward primers contained an AscI site, followed by a rabbit splice site. Reverse primers contained a rabbit recombination signal sequence (RSS) and a MluI restriction site. PCR products were gel purified using the GENECLEAN kit.
Human VHs, V3-33, V3-74, V3-49, V3-21, V3-48, V3-73, V3-7, and V3-D could not be isolated by PCR and were synthesized chemically (BlueHeron, Bothel, Wash.). Restriction sites and rabbit regulatory sequences were added during synthesis.
Rabbit spacer sequences were amplified using BACs 38A2 and 225P18 as templates and primers SEQ ID NOs 271-288 (Table 2). BAC 225P18 was double digested with NheI and a 41 kb fragment was gel purified. This fragment served as a template for the amplification of spacers V1-2, V2-3, V3-4, V4-5, and V5-6.
BAC 225P18 was digested with BstBI and the template for spacers V6-7 and V7-8 was gel-purified. A double digestion of BAC 38A2 with PacI and RsrlI allowed gel purification of the template for spacers V21-22, and V22-23.
Amplified spacer sequences were gel-purified, and subcloned into XL-PCR-TOPO™ (Invitrogen) according to the manufacturer's instructions.
VH elements and rabbit spacer sequences were sub-cloned into modified pGEM (Promega) and pBS (Strategene) vectors. The pGEM vector was cut with NotI and Hind III and ligated with chemically synthesized oligonucleotide sequences containing FseI, AscI and MluI sites (Oligo1: SEQ ID NO: 289; Oligo2: SEQ ID NO: 290; Table 2). Vector pBS was cut with SacI and KpnI and ligated with a chemically synthesized oligonucleotide sequence containing the restriction sites FseI, AscI and MluI (Oligo1: (SEQ ID NO: 291; Oligo2: SEQ ID NO: 292, Table 2).
Gentamycin and neomycin selection cassettes were amplified using primers (SEQ ID NOs: 293-296, Table 2) with Fse I or AscI sites and ligated into the modified pGEM and pBS-vectors.
The final construct is built in a modified pBeloBAC II vector. The pBeloBAC II vector was opened with BamHI and HindIII and the cloning sites were modified to contain FseI, AscI, MluI sites using a chemically synthesized oligonucleotide sequence (Oligo1: SEQ ID NO: 297; Oligo2: SEQ ID NO: 298, Table 2).
BAC 219D23 was modified by introduction of restriction sites using ET-cloning (Muyrers et al., Nucleic Acids Research 27, 1555-1557 (1999); Muyers et at Trends Biochem. Sci. 26(5):325-31 (2001)). The Neomycin selection cassette was amplified with primers SEQ ID NO: 299 and SEQ ID NO: 300 (Table 2). The forward primer contained an FseI site, the reverse primer an AscI site.
The purified PCR product was transformed into E. coli cells carrying BAC 219D23 and plasmid pSC101 necessary for homologous recombination. After homologous recombination of the cassette and the target sites in the BAC, introduced restriction sites were confirmed by restriction analysis. Subsequently, the modified BAC 219D23 was digested with FseI and MluI and the resulting 17 kb fragment (containing the FseI-Neo-AscI cassette) was separated by PFGE and purified by electro-elution. This purified fragment was ligated with the modified pBeloBAC II vector opened with FseI and MluI.
A purified DNA fragment encoding a human VH element is ligated with the modified pGEM.neo vector opened with AscI and MluI. Similarly a spacer sequence is sub-cloned into the modified pGEM.genta vector. Subsequently, the pGEM.genta vector carrying the spacer sequence is cut with FseI and MluI and the insert is ligated with pGEM.neo.VH vector opened with FseI and AscI. This step is repeated several times to build a fragment consisting of several spacer and VH segments. Such fragments are excised with FseI and MluI and ligated with the modified pBeloBAC II vector linearized with FseI and AscI. These processes are repeated to build a large immunoglobulin V region (
Screening of a rabbit genomic BAC libraries resulted in the identification of three BACs (215M22, 179L1 and 196O2; Gene Bank Accession Nos: AY495826, AY495827, and AY495828, respectively) containing rabbit light chain K1 gene segments. Rabbit Cκ□ was exchanged with human Cκ□ allotype Km3 by ET cloning as described (E-Chiang Lee et al., Genomics 73, 56-65 (2001); Daiguan Yu et al., PNAS 97, 5978-5983 (2000); Muyrers et al., Nucleic Acids Research 27, 1555-1557 (1999); Zhang et al., Nature Biotechnology 18, 1314-1317 (2000)). Human Cκ (allotype Km3) was amplified by PCR with primers (SEQ ID Nos 301 and 302, Table 2) containing 50 bp sequences homologous to target sequences. Homology arms were designed based on the published sequence of rabbit germline kappa (b5; GenBank Accession No. K01363) and matched the intron-exon boundary of Cκ. The exchange of rabbit Cκagainst the human Cκ in BAC 179L1 was verified by sequencing.
BAC 179L1-huCk was modified by two ET cloning. A neomycin selection cassette was amplified with primers (SEQ ID NOs 303 and 304, Table 2) containing 50 bp sequences homologous to BAC 179L1. The forward primer additionally had an i-CeuI meganuclease site. The PCR product was used for ET cloning. Positive clones were selected with neomycin and checked for correctness by restriction enzyme digests and sequencing. A zeocin selection cassette was amplified with primers (SEQ ID NOs 305 and 306, Table 2) containing 50 bp sequences homologous to BAC 179L1. The forward primer additionally had an i-SceI meganuclease site. The PCR product was used for ET cloning. Positive clones were selected with zeozin and checked for correctness by restriction enzyme digests and sequencing.
BAC 215M22 was modified by one ET cloning. A gentamycin resistance gene was amplified with primers (SEQ ID NOs 307 and 308, Table 2) containing 50 bp sequences homologous to BAC215M22. The forward primer additionally had an i-CeuI Meganuclease site and the reverse primer an i-SceI meganuclease site. The PCR product was used for ET cloning. Resulting clones were selected with gentamycin and analyzed by restriction enzyme digests and sequencing.
Modified BAC179L1 and 225M22 were cut with i-CeuI and i-SceI. Fragments of 98 kb and 132 kb were purified and ligated. Resulting clones were selected with kanamycin and chloramphenicol and checked for correctness by restriction enzyme digests, PCR of the regions containing i-SceI and i-CeuI restriction sites, and sequencing. The resulting BAC was termed 179-215-huCk.
Rabbit Jκ1 and Jκ2 of BAC 179-215-huCk were replaced by ET cloning with a synthetic human rearranged VκJκ gene. A DNA fragment with rabbit promoter, rabbit leader, rabbit intron and human VκJκ gene was synthesized chemically. The codon usage of the synthetic human VJ was optimised to achieve highest DNA sequence homology to rabbit V kappa genes.
The synthetic human VJ was PCR amplified with a forward primer (SEQ ID NO 309, Table 2) containing 50 bp sequences homologous to BAC 179L1 and a reverse primer (SEQ ID NO 310, Table 2) containing a sequence homologous to the gentamycin resistance gene and a FRT site. A gentamycin resistance gene was amplified with a forward primer (SEQ ID NO 311, Table 2) containing a FRT site and a reverse primer (SEQ ID NO 312, Table 2) with 50 bp homology to BAC 179L1 and a FRT site. The human synthetic human VJ and the gentamycin resistance gene were combined by overlap extension PCR using the forward primer for the synthetic human VJ gene and the reverse primer for the gentamycin resistance gene. The resulting fragment was used for ET cloning. Positive clones were selected with gentamycin and checked for correctness by restriction enzyme digests and sequencing.
The gentamycin resistance gene was removed by site specific recombination via expression of Flp recombinase. After recombination one FRT was left. The FRT site was deleted by ET cloning. A 232 bp fragment from the synthetic human VJ was amplified by PCR (using primers SEQ ID NOs 313 and 314, Table 2) and used for ET cloning. Resulting colonies were screened by PCR (using primers SEQ ID NOs 315 and 316, Table 2) for loss of the FRT site and confirmed by sequencing.
The neomycin resistance gene of BAC179-215-huCk was replaced by ET cloning. A gentamycin resistance (pRepGenta; Genebridges) gene was amplified by PCR with primers (SEQ ID NOs 317 and 318, Table 2) containing 50 bp sequences homologous to BAC 179-215-huCk. The forward primer additionally had a loxP site, an attB site and a PvuI restriction site. Resulting clones were selected with gentamycin and checked for correctness by restriction enzyme digests and sequencing.
The resulting BAC (rLC3-B;
Screening of a rabbit genomic BAC libraries resulted in the identification of three BACs (215M22, 179L1 and 196O2; Gene Bank Accession Nos: AY495826, AY495827, and AY495828, respectively) containing rabbit light chain K1 gene segments. Rabbit Cκ□0 was exchanged with human Cκ□ allotype Km3 by ET cloning as described (E-Chiang Lee et al., Genomics 73, 56-65 (2001); Daiguan Yu et al., PNAS 97, 5978-5983 (2000); Muyrers et al., Nucleic Acids Research 27, 1555-1557 (1999); Zhang et al., Nature Biotechnology 18, 1314-1317 (2000)). Human Cκ allotype Km3) was amplified by PCR with primers (SEQ ID Nos 301 and 302, Table 2) containing 50 bp sequences homologous to target sequences. Homology arms were designed based on the published sequence of rabbit germline kappa (b5; GenBank Accession No. K01363) and matched the intron-exon boundary of Cκ. The exchange of rabbit Cκ against the human Cκ in BAC 179L1 was verified by sequencing.
Two DNA fragments, Unit1 (12,235 bp,
Units 1 and 2 were digested with the restriction enzyme NgoMIV and AsiSI or NgoMIV and AscI respectively and ligated into pBELOBAC11 with a modified linker by three fragment ligation. The modified linker contained a BsiWI restriction site, a FRT5-site, a rpsL-Neo-cassette, a AscI site and a AsiSI-site. The linker fragment was amplified with High fidelity polymerase (Roche), primers CE_1_001_012904 (SEQ ID NO 319, Table 2) and CE_1_on005_013004 (SEQ ID NO 320, Table 2) and plasmid pRpsL-Neo (Genebridges) as template. Subsequently, the amplified product was ligated into BamHI and HindIII sites of pBELOBAC11. For ligation with Unit 1 and 2 the modified pBELOBAC11 was opened with AsiSI and AscI. Positive clones (pBELOBAC11 Unit1/2) were checked by restriction enzyme digests.
BAC 179L1 (GENBANK Acc. No. AY495827) was modified by insertion of two modified selection cassettes by ET cloning. Cassette 1 was a gentamycin resistance gene amplified with primers (SEQ ID Nos 321 and 322, Table 2) containing 50 bp sequences homologous to BAC 179L1 and an AscI site in the reverse primer. Cassette 2 was a rpsl-Neo selection cassette amplified with primers (SEQ ID Nos 323 and 324, Table 2) containing 50 bp sequences homologous to BAC 179L1 and an attB site, a FRT5 site and a BsiWI site in the forward primer.
The purified PCR products were transformed into E. coli cells carrying the BAC and plasmid pSC101 necessary for homologous recombination. After homologous recombination successful modification of the BAC was confirmed by restriction digest analyses, Southern Blot and sequencing.
Modified BAC 179L1 was cut with the restriction enzymes AscI and BsiWI. The fragment containing the human Cκ was purified and ligated with pBELOBAC11 Unit1/2 opened with the same restriction enzymes. Positive clones were checked by restriction enzyme digests. The final construct (
The construct described in example 6 was modified by ET cloning as follows: an. The rearranged functional VJ sequence was exchanged with a functional V1 flanked by a functional recombination signal sequence (RSS). The RSS was PCR amplified from BAC179L1 with a forward primer (SEQ ID NO 325, Table 2) containing a 50 bp sequence homologous to V1 of pBELOBAC11 Unit1/2 and a reverse primer (SEQ ID NO 326, Table 2) containing an AscI restriction enzyme site and homology to the gentamycin resistance gene. A gentamycin resistance gene was amplified with a forward primer (SEQ ID NO 327, Table 2) containing a sequence homologous to the reverse primer used for RSS amplification and a reverse primer (SEQ ID NO 328, Table 2) containing a 50 bp sequence homologous to pBELOBAC11 Unit1/2 and a BsiWI restriction enzyme site.
The RSS and the gentamycin resistance gene were combined by overlap extension PCR using the forward primer for RSS amplification and the reverse primer for Gentamycin resistance gene amplification. The resulting fragment was used to modify pBELOBAC11 Unit1/2 by ET cloning. Positive clones were selected with gentamycin and analyzed by restriction enzyme digests and sequencing.
BAC 179L1 with human Cκ was further modified by ET cloning. A kanamycin selection cassette was amplified with a primers (SEQ ID NO 329 and 330, Table 2) containing 50 bp sequences homologous to BAC 179L1. The reverse primer contained also an AscI restriction enzyme site and a FRT site. The PCR product was used for ET cloning. An ampicillin selection cassette was amplified with primers (SEQ ID Nos 331 and 332, Table 2) containing 50 bp sequences homologous to BAC 179L1. The forward primer contained also an attB site, an AsiSI restriction enzyme site and a FRT5 site The reverse primer contained a BsiWI restriction enzyme site and a FRT site. The PCR product was used for ET cloning. The human J region was amplified from human genomic DNA with primers (SEQ ID Nos 333 and 334, Table 2) containing 50 bp sequences homologous to BAC 179L1. The PCR product was used for ET cloning. The resulting clones were analyzed by restriction enzyme digest and sequencing.
A positive clone was cut with AscI and BsiWI. The resulting fragment was purified and ligated into the modified pBELOBAC11 Unit1/2 cut with the same enzymes. Positive clones were selected with ampicillin and analyzed by restriction enzyme digests and sequencing. Correct clones are used to generate transgenic animals.
Screening of a rabbit genomic BAC libraries resulted in the identification of three BACs (215M22, 179L1 and 196O2; Gene Bank Accession Nos: AY495826, AY495827, and AY495828, respectively) containing rabbit light chain K1 gene segments. Rabbit Cκ1 was exchanged with human Cκ□ allotype Km3 by ET cloning as described (E-Chiang Lee et al., Genomics 73, 56-65 (2001); Daiguan Yu et al., PNAS 97, 5978-5983 (2000); Muyrers et al., Nucleic Acids Research 27, 1555-1557 (1999); Zhang et al., Nature Biotechnology 18, 1314-1317 (2000)). Human Cκ allotype Km3) was amplified by PCR with primers (SEQ ID NOs 301 and 302, Table 2) containing 50 bp sequences homologous to target sequences. Homology arms were designed based on the published sequence of rabbit germline kappa (b5; GenBank Accession No. K01363) and matched the intron-exon boundary of Cκ. The exchange of rabbit Cκ against the human Cκ in BAC 179L1 was verified by sequencing.
Human Vκ elements of the Vκ1 family (O2, L8, L4, A30, L11, L1, L5, L15, O8, L19, L12, A20, O4, L14, L23, L9, A4, L24, O6, L22, A9, A25, A15, O9) were amplified by PCR using primers (SEQ ID NOs 335-382, Table 2) and human genomic DNA as a template.
Amplification products were analysed by gel-electrophoresis, gel purified using GENECLEAN (Q-Biogen), subcloned into the Zero-Blunt TOPO™ vectors (Invitrogen) and sequenced. A rearranged human Vκ (O2) Jκ (J4) element was produced by PCR amplification, subcloned and sequenced. To combine human Vκ elements with rabbit spacers, human Vκ elements were amplified by PCR with primers (SEQ ID Nos 383-430, Table 2) using plasmid DNA as a template. Primers contained AscI or MluI sites.
Rabbit spacer sequences are amplified by PCR using primers SEQ ID NOs 431-450 (Table 2). BACs 179L1 and 215M22 are digested with SpeI, NheI, AclI, SfoI, MluI, and SalI/XhoI. Fragments are gel purified and used as amplification templates.
The spacer sequence located at the 5-end is amplified by an upstream oligonucleotide containing a FRT and an attB site. PCR products are gel purified using the GENECLEAN kit and subcloned into XL-PCR-TOPO™ (Invitrogen) according to the manufacturer's instructions.
Human Vk elements and rabbit spacer sequences were cloned into pGem (Promega) modified as described in Example 4.
Human V kappa and the modified pGEM.genta vector are digested with AscI and MluI and ligated. Similarly, rabbit spacer sequences are cloned into pGEM.neo. Subsequently, pGem.neo. Vκ is cut with FseI and AscI and ligated with a purified insert of pGem.genta.spacer excised with FseI and MluI. Ligation of AscI and MluI complementary ends destroys the restriction enzyme site and allows repeated use of AscI and MluI for the construction of a Vκ locus comprising several Vκ and spacer elements. The final construct, consisting of fragments of a humanized BAC 179L1 and 215M22 and a humanized Vκ region is built in pBeloBAC. BAC 179L1 and 215M22 were modified and combined. Subsequently, BAC 179L1-215M22-huCk was further modified by ET cloning. Two cassettes containing restriction enzyme site, selection markers, and additional functional sites were inserted into the vector by ET-cloning as shown in
To built the final construct, units consisting of human V elements, rabbit spacer elements and a resistance marker are excised out of pGEM with FseI and MluI and ligated with BAC 179L1-215M22 digested with FseI and AscI. Subsequently, the resistance marker is replaced with a new insert consisting of human V elements, rabbit spacer elements and another resistance marker. After several repeats the final construct will consist of many Vk segments (L8, L4, A30, L11, L1, L5, L15, O8, L19, L12, A20, O4, L14, L23, L9, A4, L24, O6, L22, A9, A25, A15, O9) separated by rabbit spacer sequences. The humanized light chain locus is used for the generation of transgenic animals.
A synthetic humanized heavy chain locus containing a rabbit D region, a human J region, human Cμ, human Cγ, rabbit Cα4, the rabbit 3′α enhancer and human VH elements (including promotor and nonamer/heptamer sequences) separated by chicken spacer sequences is constructed.
Modified rabbit BAC 27N5 (see “Example 2) was further modified by ET cloning. The construct contained a humanized Cμ and Cγ and two unique restriction sites, BsiWI and AsiSI downstream of the α-4 membrane exon. DNA is amplified with oligonucleotides SEQ ID Nos 455 and 456 (Table 2).
Fosmid Fos15B is digested with NheI and the resulting 13 kb fragment containing the 3′α enhancer is subcloned into a cloning vector in such a way that the insert is flanked by BsiWI and AsiSI sites. Subsequently, the insert is excised with BsiWI and AsiSI and ligated with the modified BAC 27N5 to form BAC 27N5Fos.
The rabbit J region in BAC219D23 was exchanged with the corresponding human J region by ET cloning. The human J region was amplified by PCR using primers SEQ ID NOs 457 and 458 (Table 2).
Unique restriction enzyme sites are inserted in BAC219D23 upstream of the D region (A) and upstream of Cμ(B)□. In BAC 27N5Fos restriction site A is inserted upstream of the linker region and B is inserted in sequences homologous to BAC219D23. Following digestion with enzymes A and B, the fragment containing human J and rabbit D regions is isolated and ligated with BAC 27N5Fos to create BAC 219D23/27N5Fos.
Chicken heavy chain spacer sequences are amplified from chicken genomic DNA by PCR using primers (SEQ ID NOS 459 and 460, Table 2) specific for chicken heavy chain V pseudogenes (Mansikka et al., J Immunol 145(11), 3601-3609 (1990), Reynaud et al., Cell 59(1), 171-183 (1989)). Alternatively, spacer sequences are synthesized chemically.
The PCR products are gel purified, cloned into pTOPO (Invitrogen) and sequenced.
Human heavy chain variable elements are amplified by PCR using primers designed according to published sequences in GENBANK (eg Acc. No. NG_001019) or synthesized chemically. The human V elements contain the human promoter region, the human leader sequence, the human intron between leader and V-coding region, the human V-coding region and the human recombination signal sequence. The amplified or synthesized fragments are flanked by specific restriction endonuclease recognition. Chicken spacer sequences and human V elements are combined in one or several large DNA fragment comprising a humanized immunoglobulin locus. The construct is used to generate transgenic animals.
A BAC library generated with non-human genomic DNA is screened with probes specific for immunoglobulin and BAC clones containing heavy and light chain immunoglobulin C, J and D regions are identified. The BAC clones are modified to contain restriction enzyme sites. Human heavy and light chain variable elements are amplified by PCR using primers designed according to published sequences in GenBank (eg., Acc. No. NG_001019). Sequences are amplified from genomic DNA or synthesized chemically. The human V elements contain the human promoter region, the human leader sequence, the human intron between leader and V-coding region, the human V-coding region and the human recombination signal sequence (RSS). The amplified or synthesized fragments have specific restriction endonuclease recognition sites at the ends. The non-human spacer sequences are amplified by PCR or synthesized chemically. Non-human spacer sequences and human V elements are combined in one or several large DNA fragment comprising a humanized immunoglobulin locus. The construct is used to generate transgenic animals. An example for the construction of a humanized V region using chicken spacer sequences is shown in
A BAC library generated with non-human genomic DNA is screened with probes specific for immunoglobulin and BAC clones containing heavy and light chain immunoglobulin C, J and D regions are identified. The BAC clones are modified to contain restriction enzyme sites. Human heavy and light chain variable elements are amplified by PCR using primers designed according to published sequences in GenBank (eg., Acc No. NG_001019). Sequences are amplified from genomic DNA or synthesized chemically. The human V elements contain the human V coding region. Non-human spacer sequences are amplified by PCR or synthesized chemically and contain a recombination signal sequence, a spacer sequence, a promoter region, a leader sequence and the intron between leader and V coding region. Such non-human spacer sequences are combined with human V elements in one or several large DNA fragments and used for the generation of transgenic animals. An example for the construction of a humanized V region using mouse or rabbit spacer sequences is shown in
Transgenic rabbits were generated as described by Fan et al. (Pathol. Int. 49: 583-594, 1999). Briefly, female rabbits are superovulated using standard methods and mated with male rabbits. Pronuclear-stage zygotes are collected from oviduct and placed in an appropriate medium such as Dulbecco's phosphate buffered saline supplemented with 20% fetal bovine serum. BAC containing humanized immunoglobulin loci were microinjected into the male pronucleus with the aid of a pair of manipulators. Morphological surviving zygotes were transferred to the oviducts of pseudopregnant rabbits. Pseudopregnancy was induced by the injection of human chorionic gonadotrophin (hCG). Following injection of a humanized light chain construct into 4645 pronuclei of fertilized oocytes, 4043 oocytes were transferred into 132 recipients. In total, 253 live offspring were born, 11 of which were transgenic. Expression of human kappa light chain was detected by ELISA using human-kappa light chain specific reagents (for example, mouse anti-human Kappa, Southern Biotech, 9220-01; goat anti-human Kappa, Southern Biotech 2063-08).
A humanized heavy chain construct was injected into 4083 pronuclei of fertilized oocytes. 3485 oocytes were transferred into 119 recipients which delivered 433 offspring. Analysis by PCR and FISH revealed that 20 of these animals were transgenic. Humanized heavy chain in the blood of founder animals was detected by ELISA using antibodies specific for human IgM/IgG (for example, rabbit anti-human IgM, Rockland 609-4131; rabbit anti-human IgM, Rockland 609-4631; rabbit anti-human IgG, Pierce 31142, rabbit anti-human IgG, Southern Biotech 6145-08; rabbit anti-human IgG, Pierce 31784).
Sandwich-type ELISAs detecting humanized κ, μ and γ chains were performed using standard procedures. Briefly, microtiter plates were coated with capture antibody and incubated with diluted serum samples. Bound human immunoglobulin was detected using a secondary labeled antibody and peroxidase-streptavidin-conjugate (Sigma, S2438).
Double transgenic animals expressing both humanized heavy and light immunoglobulin chains were generated by breeding of founder animals.
Transgenic mice were generated as described by Nagy et al. (Manipulating the Mouse Embryo: A Laboratory Manual; Cold Spring Harbor Laboratory Press, New York, 2003). Briefly, female mice were superovulated using standard methods and mated with male mice. Pronuclear-stage zygotes were collected from oviduct and placed in a suitable medium such as M2 medium. BAC containing humanized immunoglobulin loci were microinjected into the male pronucleus with the aid of a pair of manipulators. Morphologically surviving zygotes were transferred to the oviducts of pseudopregnant female mice. Pseudopregnancy was induced by mating with sterile males. Following injection of a humanized light chain construct into 1325 pronuclei of fertilized oocytes, 787 oocytes were transferred into 29 recipients. In total, 55 live offspring were born, 11 of which were transgenic.
A humanized heavy chain construct was injected into 1050 pronuclei of fertilized oocytes. 650 oocytes were transferred into 25 recipients which delivered 64 live offspring. Analysis by PCR revealed that 19 of these animals were transgenic.
Double transgenic animals expressing both humanized heavy and light immunoglobulin chains are generated by breeding of founder animals. Expression of humanized κ, μ and γ chains was detected by ELISAs using standard procedures. Briefly, microtiter plates were coated with capture antibody and incubated with diluted serum samples. Bound human immunoglobulin was detected using a secondary labeled antibody and peroxidase-streptavidin-conjugate (Sigma, S2438).
All references cited throughout the specification are hereby expressly incorporated by reference. While the invention is illustrated by reference to certain embodiments, it is not so limited. One skilled in the art will recognize that various modifications and variations are possible without diverting from the essence of the invention. All such modifications and variations are specifically included within the scope herein.
TABLE 1
ID
BAC
Accession#
Start
Finish
Description
1
38A2
AY386694
1
2137
Spacer 5′ start-V34
2
38A2
AY386694
2433
9504
Spacer V34-V33
3
38A2
AY386694
9798
19384
Spacer V33-V32
4
38A2
AY386694
19690
35164
Spacer V32-V31
5
38A2
AY386694
35447
47669
Spacer V31-V30
6
38A2
AY386694
47973
52521
Spacer V30-V29
7
38A2
AY386694
52819
61798
Spacer V29-V28
8
38A2
AY386694
62100
74264
Spacer V28-V27
9
38A2
AY386694
74566
79145
Spacer V27-V26
10
38A2
AY386694
79449
84800
Spacer V26-V25
11
38A2
AY386694
85103
95717
Spacer V25-V24
12
38A2
AY386694
96009
102226
Spacer V24-V26
13
38A2
AY386694
102504
105307
Spacer V23-V22
14
38A2
AY386694
105603
107583
Spacer V22-V24
15
38A2
AY386694
107769
118033
Spacer V24-V20
16
38A2
AY386694
118334
125546
Spacer V20-V19
17
38A2
AY386694
125849
128059
Spacer V19-3′ end
18
225P18
AY386697
1
4333
Spacer 5′ start-V18
19
225P18
AY386697
4629
9255
Spacer V18-V17
20
225P18
AY386697
9561
15841
Spacer V17-V16
21
225P18
AY386697
16135
22502
Spacer V16-V15
22
225P18
AY386697
22794
32821
Spacer V15-V14
23
225P18
AY386697
33118
37738
Spacer V14-V13
24
225P18
AY386697
38044
44571
Spacer V13-V12
25
225P18
AY386697
44865
49447
Spacer V12-V11
26
225P18
AY386697
49745
56909
Spacer V11-V10
27
225P18
AY386697
57205
63678
Spacer V10-V9
28
225P18
AY386697
63977
71204
Spacer V9-V8
29
225P18
AY386697
71507
76261
Spacer V8-V7
30
225P18
AY386697
76560
79012
Spacer V7-V6
31
225P18
AY386697
79308
83467
Spacer V6-V5
32
225P18
AY386697
83768
88013
Spacer V5-V4
33
225P18
AY386697
88314
91233
Spacer V4-V3
34
225P18
AY386697
91531
95929
Spacer V3-V2
35
225P18
AY386697
96233
100963
Spacer V2-V1
36
225P18
AY386697
101262
133721
Spacer V1-D3
37
225P18
AY386697
133752
135212
Spacer D3-D1a
38
225P18
AY386697
135237
136922
Spacer D1a-D4
39
225P18
AY386697
136947
139446
Spacer D4-3′ end
40
219D23
AY386695
8151
40612
Spacer V1-D3
41
219D23
AY386695
40643
42102
Spacer D3-D1a
42
219D23
AY386695
42127
43812
Spacer D4-D1b
43
219D23
AY386695
43837
48553
Spacer D1b-D6
44
219D23
AY386695
48577
48753
Spacer D6-D8
45
219D23
AY386695
48769
51181
Spacer D8-D2x
46
219D23
AY386695
51213
55826
Spacer D1c-Df
47
219D23
AY386695
55852
61112
Spacer Df-D1d
48
219D23
AY386695
61237
62445
Spacer D1d-D5
49
219D23
AY386695
62471
97024
Spacer D5-DQ52
50
219D23
AY386695
97036
97831
Spacer DQ52-J1
51
219D23
AY386695
97871
98090
Spacer J1-J2
52
219D23
AY386695
98140
98430
Spacer J2-J3
53
219D23
AY386695
98483
98642
Spacer J3-J4
54
219D23
AY386695
98690
98981
Spacer J4-J5
55
219D23
AY386695
99032
99550
Spacer J5-J6
56
219D23
AY386695
99604
106867
1501Spacer J6-
IgM exon1
57
219D23
AY386695
107185
107290
Spacer IgM exon1-
exon2
58
219D23
AY386695
107635
107863
Spacer IgM exon2-
exon3
59
219D23
AY386695
108181
108268
Spacer IgM exon3-
exon4
60
219D23
AY386695
108664
110499
Spacer IgM exon4-
exonM1
61
219D23
AY386695
110615
110741
Spacer exonM1-
exonM2
62
219D23
AY386695
108664
137302
Spacer IgM exon4-
3′ end
63
27N5
AY386696
5099
55582
Spacer IgM exon4-
IgG exon1
64
27N5
AY386696
55867
56071
Spacer IgG exon1-
exon2
65
27N5
AY386696
56104
56201
Spacer IgG exon2-
exon3
66
27N5
AY386696
56531
56623
Spacer IgG exon3-
exon4
67
27N5
AY386696
56946
58984
Spacer IgG exon4-
exonM1
68
27N5
AY386696
56946
59205
Spacer IgG exon4-
exonM2
69
27N5
AY386696
56946
69246
Spacer IgG exon4-
IgE exon1
70
27N5
AY386696
69546
69719
Spacer IgE exon1-
exon2
71
27N5
AY386696
70037
70132
Spacer IgE exon2-
exon3
72
27N5
AY386696
70453
70532
Spacer IgE exon3-
exon4
73
27N5
AY386696
70873
73061
Spacer IgE exon4-
exonM1
74
27N5
AY386696
70873
73292
Spacer IgE exon4-
exonM2
75
27N5
AY386696
70873
86059
Spacer IgE exon4-
IgA4 exon1
76
27N5
AY386696
86362
86498
Spacer IgA4 exon1-
exon2
77
27N5
AY386696
86876
87059
Spacer IgA4 exon2-
exon3
78
27N5
AY386696
87450
89577
Spacer IgA4 exon3-
exonM
79
27N5
AY386696
87450
103798
Spacer IgA4 exon3-
IgA5b exon1
80
27N5
AY386696
104101
104231
Spacer IgA5b exon1-
exon2
81
27N5
AY386696
104609
104787
Spacer IgA5b exon2-
exon3
82
27N5
AY386696
105182
107227
Spacer IgA5b exon3-
exonM
83
27N5
AY386696
105182
112077
Spacer IgA5b exon3-
exonM
84
27N5
AY386696
105182
119223
Spacer IgA5b exon3-
IgA1 exon1
85
27N5
AY386696
119511
119644
Spacer IgA1 exon1-
exon2
86
27N5
AY386696
119984
120162
Spacer IgA1 exon2-
exon3
87
27N5
AY386696
120557
122823
Spacer IgA1 exon3-
exonM
88
27N5
AY386696
120557
127750
Spacer IgA1 exon3-
exonM*
89
27N5
AY386696
120557
135838
Spacer IgA1 exon3-
IgA2 exon1
90
27N5
AY386696
136138
136274
Spacer IgA2 exon1-
exon2
91
27N5
AY386696
136652
136831
Spacer IgA2 exon2-
exon3
92
27N5
AY386696
137229
139433
Spacer IgA2 exon3-
exonM
93
27N5
AY386696
137229
146676
Spacer IgA2 exon3-
3′ end
94
Fos15B
AY386698
1
828
Spacer 5′ start-IgA
exonM
95
Fos15B
AY386698
1043
3596
Spacer IgA exonM-
end contig1
96
Fos15B
AY386698
1
3596
Spacer 5′ start-end
contig1
97
Fos15B
AY386698
7404
7541
Spacer IgA exon1-
exon2
98
Fos15B
AY386698
7908
8086
Spacer IgA exon2-
exon3
99
Fos15B
AY386698
8481
10538
Spacer IgA exon3-
exonM
100
Fos15B
AY386698
8481
13140
Spacer IgA exon3-
end contig2
101
Fos15B
AY386698
8481
15871
Spacer IgA exon3-
1,2 hs 3′ enh
102
Fos15B
AY386698
8481
21447
Spacer IgA exon3-
4hs enh
103
Fos15B
AY386698
21484
33297
Spacer 4hs enh-end
contig4
104
Fos15B
AY386698
16633
33297
Spacer 1,2hs 3′ enh-
end contig4
105
179L1
AY495827
1
124285
Spacer 5′ end-enh
106
179L1
AY495827
125411
131350
Enhancer-C□
107
179L1
AY495827
131664
134637
Spacer C□-J5
108
179L1
AY495827
134684
134915
Spacer J5-J4
109
179L1
AY495827
134952
135196
Spacer J4-J3
110
179L1
AY495827
135241
135485
Spacer J3-J2
111
179L1
AY495827
135525
135863
Spacer J2-J1
112
179L1
AY495827
135897
155257
Spacer J1-V1
113
179L1
AY495827
155572
170621
Spacer V1-V2
114
179L1
AY495827
170936
173443
Spacer V2-V3
115
179L1
AY495827
173752
177227
Spacer V3-V4
116
179L1
AY495827
177536
185356
Spacer V4-V5
117
179L1
AY495827
185664
200758
Spacer V5-V6
118
179L1
AY495827
201064
203580
Spacer V6-V7
119
179L1
AY495827
203886
205144
Spacer V7-3′ end
120
215M22
AY495826
1
12829
Spacer 5′ end-V6
121
215M22
AY495826
13136
15653
Spacer V6-V7
122
215M22
AY495826
15957
22241
Spacer V7-V8
123
215M22
AY495826
22551
32876
Spacer V8-V9
124
215M22
AY495826
33188
38276
Spacer V9-V10
125
215M22
AY495826
38582
41476
Spacer V10-V11
126
215M22
AY495826
41780
47827
Spacer V11-V12
127
215M22
AY495826
48133
48547
Spacer V12-V13
128
215M22
AY495826
48841
51408
Spacer V13-V14
129
215M22
AY495826
51638
55438
Spacer V14-V15
130
215M22
AY495826
55745
67437
Spacer V15-V16
131
215M22
AY495826
67743
77805
Spacer V16-V17
132
215M22
AY495826
78120
80628
Spacer V17-V18
133
215M22
AY495826
80937
84009
Spacer V18-V19
134
215M22
AY495826
84315
87339
Spacer V19-V20
135
215M22
AY495826
87648
89399
Spacer V20-V21
136
215M22
AY495826
89711
95414
Spacer V21-V22
137
215M22
AY495826
95720
106650
Spacer V22-V23
138
215M22
AY495826
106956
110940
Spacer V23-V24
139
215M22
AY495826
111246
117877
Spacer V24-V25
140
215M22
AY495826
118183
122396
Spacer V25-V26
141
215M22
AY495826
122706
126496
Spacer V26-V27
142
215M22
AY495826
126802
133358
Spacer V27-V28
143
196O2
AY495828
37134
48826
Spacer V15-V16
144
196O2
AY495828
49032
59195
Spacer V16-V17
145
196O2
AY495828
115057
125885
Spacer V28-V29
146
196O2
AY495828
126195
130012
Spacer V29-V30
147
196O2
AY495828
130318
136966
Spacer V30-V31
148
196O2
AY495828
137272
144512
Spacer V31-V32
149
196O2
AY495828
144819
148617
Spacer V32-V33
150
196O2
AY495828
148923
155402
Spacer V33-V34
151
196O2
AY495828
155714
171415
Spacer V34-V35
152
196O2
AY495828
171572
177676
Spacer V35-V36
153
196O2
AY495828
177979
178083
Spacer V36-3′ end
154
CLC*
NA
1
443
Spacer 5′ end-
pV28**
155
CLC*
NA
486
1203
Spacer pV28-
Pv27**
156
CLC*
NA
1528
1635
Spacer pV27-
pV26**
157
CLC*
NA
1818
2242
Spacer pV26-
pV25**
158
CLC*
NA
2585
2676
Spacer pV25-
pV24**
159
CLC*
NA
2781
3327
Spacer pV24-
pV23**
160
CLC*
NA
3464
3659
Spacer pV23-
pV22**
161
CLC*
NA
3985
4241
Spacer pV22-
pV21**
162
CLC*
NA
4578
4994
Spacer pV21-
pV20**
163
CLC*
NA
5366
5425
Spacer pV20-
pV19**
164
CLC*
NA
5749
5842
Spacer pV19-
pV18**
165
CLC*
NA
6034
7043
Spacer pV18-
pV17**
166
CLC*
NA
7266
7493
Spacer pV17-
pV16**
167
CLC*
NA
7625
7625
Spacer pV16-
pV15**
168
CLC*
NA
7988
8758
Spacer pV15-
pV14**
169
CLC*
NA
9100
9410
Spacer pV14-
pV13**
170
CLC*
NA
9787
10057
Spacer pV13-
pV12**
171
CLC*
NA
10441
11022
Spacer pV12-
pV11**
172
CLC*
NA
11380
11911
Spacer pV11-
pV10**
173
CLC*
NA
12162
12349
Spacer pV10-pV9**
174
CLC*
NA
12691
13357
Spacer pV9-pV8**
175
CLC*
NA
13708
13882
Spacer pV8-pV7**
176
CLC*
NA
14229
14406
Spacer pV7-pV6**
177
CLC*
NA
14599
15338
Spacer pV6-pV5**
178
CLC*
NA
15613
16578
Spacer pV5-pV4**
179
CLC*
NA
16916
18219
Spacer pV4-pV3**
180
CLC*
NA
18439
18879
Spacer pV3-pV2**
181
CLC*
NA
19248
19343
Spacer pV2-pV1**
182
CLC*
NA
19609
22208
Spacer pV1-V**
183
CLC*
NA
22506
24313
Spacer V-J
184
CLC*
NA
24350
26088
Spacer J-C□
185
CLC*
NA
26402
36259
Spacer C-3' end
*CLC—Chicken light chain locus SEQ ID 184, FIG. 9
**pV—pseudo V gene (not functional)
Comments:
BAC sequences submitted to GenBank were modified by deletion of
vector sequences at the 5' and 3' end as follows:
BAC
Accession#
Removed from 5′ end
Removed from 3′ end
38A2
AY386694
1-125
1281285-128225
219D23
AY386695
1-54
137357-137389
Fos15B*
AY3866968
1-97
33395-33427
179L1
AY495827
0
205145-205968
196O2
AY495828
1-32
178117-178171
*In addition contigs in GenBank are separated by 50 nt. In the Fos15B
sequence submitted with the provisional application contigs were
separated by 10 nt.
TABLE 2
ID
Region
Sequence
193
VH1
5′CGCGGATCCGAGACTGGGCTGCGCTG3′
194
VH1
5′CGCAAGCTTGAAATAGGTGGCCGTGTC3′
195
JH
5′CGCGGATCCAGGCACCCTGGTCACCG3′
196
JH
5′CGCAAGCTTGTGACCAGGGTGCCCTG3′
197
Cγ
5′CGCGGATCCCTGGAGCCGAAGGTCTAC3′
198
Cγ
5′CGCAAGCTTGAGATGGACTTCTGCGTG3′
199
3'Enh
5′CGCGGATCCCAGAGTGGGTCTGTGACA3′
200
3'Enh
5′CGCAAGCTTACAGGCGCATGCAAATGC3′
201
Vκ
5′CGCGGATCCGAGGCACAGTCACCATC3′
202
Vκ
5′CGCAAGCTTACAGTAGTAAGTGGCAGC3′
203
Jκ
5′CGCGGATCCGGAGGGACCGAGGTGGT3′
204
Jκ
5′CGCAAGCTTACCATGGTCCCTGAGCC3′
205
C□
5′CGCGGATCCCCTCAGGTGATCCAGTTG3′
206
C□
5′CGCAAGCTTCTATTGAAGCTCTGGACG3′
207
K 3'Enh
5′CGCGGATCCGTGACTGGCCCAAGAAG3′
208
K 3'Enh
5′CGCAAGCTTATACAACCTTGGCCAGG3′
209
C□
5′AAACAGCTTTTCACACCTCCCCTTTCTCTCTTTGCTCCCC
TGGGCCCTCAGGGAGTGCATCCGCCCCAACCCTTTTCC3′
210
C□
5′CAGGGTTAGTTTGCATGCACACACACACAGCGCCTGGTC
ACCCAGAGGGGTCAGTAGCAGGTGCCAGCTGTGTCGGACATG3′
211
C□
5′GGTCAGGGGTCCTCCAGGGCAGGGGTCACATTGTGCCCC
TTCTCTTGCAGCCTCCACCAAGGGCCCATCGGTC3′
212
Cγ
5′CACAGCTGCGGCGTGGGGGGGAGGGAGAGGGCAGCTCG
CCGGCACAGCGCTCATTTACCCGGAGACAGGGAGAGGCTCTTC3′
213
JH
5′GTGTTATAAAGGGAGACTGAGGGGGCAGAGGCTGTGCTA
CTGGTACCTGGCTGAATACTTCCAGCACTGGGGCCAGG3′
214
JH
5′GGCCACAGAAAAGAGGAGAGAATGAAGGCCCCGGAGAG
GCCGTTCCTACCTGAGGAGACGGTGACCGTGGTCCCT TG-3′
215
Genta
5′CCAGGCCGGCCTGGAGTTGTAGATCCTCTACG3′
216
Genta
5′CCAGGCGCGCCAAGATGCGTGATCTGATCC3′
217
Linker
5′GGCCGCGGCCGGCCATCGATGGCGCGCCTTCGAAACGCGTA3′
218
Linker
5′AGCTTACGCGTTTCGAAGGCGCGCCATCGATGGCCGGCCGC3′
219
pBB11.1
5′ATTCCCAAGCTTTTAATTAAGACGTCAGCTTCCTTAGCTCCTG3′
220
pBB11.1
5′ATTCGCGGATCCACGCGTTTCGTTCCCAAAGGCGCGCCTAGCG
ATGAGCTCGGAC3′
221
Neo
5′GCAGGCATGCAAAGCTTATTACACCAGTGTCAGTAAGCG3′
222
Neo
5′GGTACCCGGGGATCCTCAGAAGAACTCGTCAAGAAGGCG3′
223
pBB11.2
5′AAATTCCCTTAATTAAGACGTCAGCTTCCTTAGCTCCTG3′
224
pBB11.2
5′GAAACCGGGGACGCGTTACCGTTCGTATAATGTATGCTATACGAA
GTTATGCGGCCGCTAGCGATGAGCTCGGAC3′
225
CA
5′TTCTCTGTTTTTGTCCGTGGAATGAACAATGGAAGTCCGAGCTCA
TCGCTAAGGGCACCAATAACTGC3′
226
CA
5′CACAGGAGAGAAACAGGACCTAGAGGATGAGGAAGTCCCTGTAG
GCTTCCTACCGTTCGTATAATGTATGCTATACGAAGTTATTACCTGT
GACGGAAGATC-3′
227
VH3-9
5′ATAGAGAGATTGAGTGTG3′
228
VH3-9
5′TCCTGTCTTCCTGCAG3′
229
VH3-11
5′AGAGACATTGAGTGGAC3′
230
VH3-11
5′AGGGAGGTTTGTGTC3′
231
VH3-13
5′ACTAGAGATATTGAGTGTG3′
232
VH3-13
5′AGGCATTCTGCAGGG3′
233
VH3-15
5′ACTAGAGAGATTAAGTGTG3′
234
VH3-15
5′TCACACTGACCTCCC3′
235
VH3-20
5′TCATGGATCAATAGAGATG3′
236
VH3-20
5′TGCAGGGACGTTTGTG3′
237
VH3-23
5′AGAAAAATTGAGTGTGAA3′
238
VH3-23
5′GTGTCTGGGCTCACAA3′
239
VH3-30
5′AGAGAGACTGAGTGTG3′
240
VH3-30
5′TGCAGGGAGGTTTGTG3′
241
VH3-43
5′TGAGTGTGAGTGAACATG3′
242
VH3-43
5′ACCAGCTCTTAACCTTC3′
243
VH3-64
5′TGAGTGTGAGTGGAC3′
244
VH3-64
5′TGACGCTGATCAGTG3′
245
VH3-66
5′TCTGACCAATGTCTCTG3′
246
VH3-66
5′AGGTTTGTGTCTGGGC3′
247
VH3-72
5′ACAAGGTGATTTATGGAG3′
248
VH3-72
5′AGGTTTGTGTCCGGG3′
249
VH3-9
5′TTGGCGCGCC TGTCGTCTGTGTTTGCAG GTGTCC3′
250
VH3-9
5′TTGCACGCGTGCAGGGAGGTTTGTGTCTGGGCTCA
GCCTGAGGGCCCCTCACTGTGTCATCTTTTGCAC3′
251
VH3-11
5′TTGGCGCGCC TGTCGTCTGTGTTTGCAG GTGTCC3
252
VH3-11
5′TTGCACGCGTGCAGGGAGGTTTGTGTCTGGGCTCA
GCCTGAGGGCCCCTCACTGTGTCTCTCG3′
253
VH3-13
5′TTGGCGCGCCTGTCGTCTGTGTTTGCAGGTGTCC3′
254
VH3-13
5′TTGCACGCGTGCAGGGAGGTTTGTGTCTGGGCTCA
GCCTGAGGGCCCCTCACTGTGTCTCTTG3′
255
VH3-15
5′TTGGCGCGCCTGTCGTCTGTGTTTGCAGGTGTCC3′
256
VH3-15
5′TTGCACGCGTGCAGGGAGGTTTGTGTCTGGGCTCA
GCCTGAGGGCCCCTCACTGTGTCTGTGG3′
257
VH3-20
5′TTGGCGCGCC TGTCGTCTGTGTTTGCAGGTGTC3′
258
VH3-20
5′TTGCACGCGTGCAGGGAGGTTTGTGTCTGGGCTC
AGCCTGAGGGCCCCTCACTGTGTCTCTC3′
259
VH3-23
5′TTGGCGCGCCTGTCGTCTGTGTTTGCAG GTGTCCAGTGTG3′
260
VH3-23
5′TTGCACGCGTGCAGGGAGGTTTGTGTCTGGGCTCAGCCTGA
GGGCCCCTCACTGTGTCTTTC3′
261
VH3-30
5′TTGGCGCGCCTGTCGTCTGTGTTTGCAGGTGTCCAGTGTC3′
262
VH3-30
5′TTGCACGCGTGCAGGGAGGTTTGTGTCTGGGCTCAGCCTG
AGGGCCCCTCACTGTGTCTTTCG3′
263
VH3-43
5′TTGGCGCGCCTGTCGTCTGTGTTTGCAGGTGTCC3′
264
VH3-43
5′TTGCACGCGTGCAGGGAGGTTTGTGTCTGGGCTCA
GCCTGAGGGCCCCTCACTGTGTCTCTTTTGCAC3′
265
VH3-64
5′TTGGCGCGCCTGTCGTCTGTGTTTGCAGGTGTCC3′
266
VH3-64
5′TTGCACGCGTGCAGGGAGGTTTGTGTCTGGGCTCA
GCCTGAGGGCCCCTCACTGTGTCTCTCGCAC3′
267
VH3-66
5′TTGGCGCGCCTGTCGTCTGTGTTTGCAGGTGTCC3′
268
VH3-66
5′TTGCACGCGTGCAGGGAGGTTTGTGTCTGGGCTCA
GCCTGAGGGCCCCTCACTGTGTCTCCG3′
269
VH3-72
5′TTGGCGCGCCTGTCGTCTGTGTTTGCAG GTTTCC3′
270
VH3-72
5′TTGCACGCGTGCAGGGAGGTTTGTGTCTGGGCTCA
GCCTGAGGGCCCCTCACTGTGTCTCTAGCAC3′
271
V1-2
5′TTGGCGCGCCAGGGGAGTGCGGCTCCAC3′
272
V1-2
5′TTGCACGCGT TGGTCAGGACACTGTCACTCAC3′
273
V2-3
5′TTGGCGCGCCAGGGGCGCGCGGCTCCAC3′
274
V2-3
5′TTGCACGCGTTGATCACGAAACTGTCACTCACACTCTC3′
275
V3-4
5′TTGGCGCGCCAGGGGCGCGCGGCTCCAC3′
276
V3-4
5′TTGCACGCGTTCTGTTGGTCTCTTCTTCTCTTGCTATAAC3′
277
V4-5
5′TTGGCGCGCCAGGGGAGTGCGGCTCCAC3′
278
V4-5
5′TTGCACGCGTTGGTCAAGACACTGTCACTCAC3
279
V5-6
5′TTGGCGCGCCAGGGACGCACGGCTCCAC3′
280
V5-6
5′TTGCACGCGTTGGTCAGGAAGCTGTCACTCAC3′
281
V6-7
5′TTGGCGCGCCAGGGATGCGCGGCTCCAG3′
282
V6-7
5′TTGCACGCGTTGGTCAGGACACTGTCACTGACAC3′
283
V7-8
5′TT GGCGCGCCAGGGGAGTGCGGCTCCAC3′
284
V7-8
5′TTGCACGCGTTGGTCAGGAAGCTGTCACTCACTCTC3′
285
V21-22
5′TTGGCGCGCCGGGGCCCGCGGCTCCAC3′
286
V21-22
5′TTGCACGCGTTGGTCAGGAAGCTGTCAC3′
287
V22-23
5′TTGGCGCGCCAGGGACGTGAGGCTCTAC3′
288
V22-23
5′TTGCACGCGTTGGTCAGGGCACTGTCAC3′
289
Linker
5′GGCCGCGGCCGGCCATCGATGGCGCGCC TTCGAAACGCGTA3′
290
Linker
3′CGCCGGCCGGTAGCTACCGCGCGGAAGCTT TGCGCATTCGA5′
291
Linker
5′CGG CCG GCC ATC GAT GGC GCG CCT TCG AAA CGC GTG GTA
C3′
292
Linker
3′TCG AGC CGG CCG GTA GCT ACC GCG CGG AAG CTT TGC GCA
C5′
293
Genta
5′CCAGGCCGGCCTGGAGTTGTAGATCCTCTACG3′
294
Genta
5′CCAGGCGCGCCAAGATGCGTGATCTGATCC-3′
295
Neo
5′CCAGGCCGGCCATTACACCAGTGTCAGTAAGCG3′
296
Neo
5′CCAGGCGCGCCTCAGAAGAACTCGTCAAGAAGGCG3′
297
Linker
5′GAT CCG GCC GGC CAT CGA TGG CGC GCC TTC GAA ACG CGT
TAG GGA TAA CAG GGT AAT A3′
298
Linker
3′GCC GGC CGG TAG CTA CCG CGC GGA AGC TTT GCG CAA TCC
CTA TTG TC CCA TTA TCGA5′
299
Neo
5′ATCTGCACTCAGTGCGTCTTGAGCGCCCCCTGGTAGAGCCG
CGCGACCCT GGCGCGCC ATTACACCAGTGTCAGTAAGCG3′
300
Neo
5′AAATGACCAGTCTGACAGCCGCGGACACGGCCACCTATTTC
TGTGCGAGA GGCCGGCC TCAGAAGAACTCGTCAAGAAGGCG3′
301
Cκ Km3
5′GATGTCCACTGGTACCTAAGCCTCGCCCTCTGTGCTTCTTCCCTC
CTCAGGAACTGTGGCTGCACCATCTGTCTTC3′
302
Cκ Km3
5′GAGGCTGGGCCTCAGGGTCGCTGGCGGTGCCCTGGCAGGCGTC
TCGCTCTAACACTCTCCCCTGTTGAAGCTCTTTGTG3
303
Neo
5′CTTTCTCTGTCCTTCCTGTGCGACGGTTACGCCGCTCCATGAGCTT
ATCGTAACTATAACGGTCCTAAGGTAGCGATGGACAGCAAGCGAA
CCGGA3′
304
Neo
5′GGACCAGTTTACAATCCCACCTGCCATCTAAGAAAGCTGGTCTCA
TCGTGTCAGAAGAACTCGTCAAGAAG3′
305
Zeo
5′CCCCCCCCGCCACTTCTCTTCTGTTTCGTTTAAGTTCTACACTGAC
ATACTAGGGATAACAGGGTAATAACGTTTACAATTTCGCCTGATG3
306
Zeo
5′AGTGGGTAGGCCTGGCGGCCGCCTGGCCGTCGACATTTAGGTGA
CACTATAGAAGGATCCTAGCACGTGTCAGTCCTGCT3′
307
Genta
5′TTACGCCAAGCTATTTAGGTGACACTATAGAATACTCAAGCTTTG
ATTGCTAACTATAACGGTCCTAAGGTAGCGATGAAGGCACGAACCC
AGTTG3′
308
Genta
5′GCGGAATTCTATGTCTAGTGGAGGGTGAAGCTGGTGATTATAGA
GTGAAAATTACCCTGTTATCCCTATCGGCTTGAACGAATTGTTAG3′
309
VJ
5′CATAAATATACTGTCTTCCAGGATCTTAGAGCTCACCTAAGGAAA
CAAGAGTTCATTTGAAGTTTTTAAAGTG3′
310
VJ
5′ACTCCAGAAGTTCCTATACTTTCTAGAGAATAGGAACTTCGGAAT
AGGAACTTCCTTTGATCTCCACCTTGGTC3′
311
Genta
5′GAAGTTCCTATTCCGAAGTTCCTATTCTCTAGAAAGTATAGGAAC
TTCTGGAGTTGTAGATCCTCTACG3′
312
Genta
5′AAAACAAACCAATCAGGCAGAAACGGTGAGGAATCAGTGAAAC
GGCCACTTACGAAGTTCCTATACTTTCTAGAGAATAGGAACTTCGG
AATAGGAACTTCAAGATGCGTGATCTGATCC3′
313
FRT
5′TTATGCTGCATCCAGTTTGC3′
314
FRT
5′AAAACAAACCAATCAGGCAG3′
315
FRT
5′TGTGACATCCAGATGAC3′
316
FRT
5′AAAACAAACCAATCAGGCAG3′
317
Genta
5′GGACCAGTTTACAATCCCACCTGCCATCTAAGAAAGCTGGTCTCA
TCGTGGTGCCAGGGCGTGCCCTTGGGCTGGGGGCGCGATAACTTCG
TATAGCATACATTATACGAAGTTATCGATCGTGGAGTTGTAGATCC
TCTACG3′
318
Genta
5′TTACGCCAAGCTATTTAGGTGACACTATAGAATACTCAAGCTTTG
ATTGCAAGATGCGTGATCTGATCCT3′
319
Linker
5′CGGGATCCGCGCGTACGGAAGTTCCTATACCTTTTGAAGAATAGG
AACTTCGGAATAGGAACTTCATTACACCAGTGTCAGTAAGCG3′
320
Linker
5′GGGAAGCTTCGCGCGATCGCCGCTTTCGCAAAGGCGCGCCTCAG
AAGAACTCGTCAAGAAGGCG3′
321
Genta
5′GGCGGCCGCCTGGCCGTCGACATTTAGGTGACACTATAGAAGGA
TCCGCGTGGAGTTGTAGATCCTCTACG3′
322
Genta
5′AACTCAGTAAGGAAAAGGACTGGGAAAGTGCACTTACATTTGAT
CTCCAGGCGCGCCAAGATGCGTGATCTGATCC3′
323
Neo
5′GGACCAGTTTACAATCCCACCTGCCATCTAAGAAAGCTGGTCTCA
TCGTGGTGCCAGGGCGTGCCCTTGGGCTGGGGGCGCGGAAGTTCCT
ATTCCGAAGTTCCTATTCTTCAAAAGGTATAGGAACTTCCGTACGA
TTACACCAGTGTCAGTAAGCG3′
324
Neo
5′GGACTGATGGGAAAATAGAGGAGAAAATTGACCAGAGGAAGTG
CAGATGGTCAGAAGAACTCGTCAAGAAGGCG3′
325
RSS
5′AACCTGAAGATTTTGCAACTTACTACTGTCAACAGAGTTACAGTA
CCCCTTCCACAGTGATACAAGCCC3′
326
RSS
5′TGCCGGCCACGATGCGTCCGGCGTAGAGGATCTACAACTCCAGG
CGCGCCTGGTCATGTCAGTGCTGCTGC3′
327
Genta
5′CTCCTTTCCTCCTCCTTGGTGGCAGCAGCACTGACATGACCAGGC
GCGCC TGGAGTTGTAGATCCTCTACG3′
328
Genta
5′TGTAATACGACTCACTATAGGGCGAATTCGAGCTCGGTACCCGGG
GATCCCGTACGAAGATGCGTGATCTGATCC3′
329
Kana
5′GGCGGCCGCCTGGCCGTCGACATTTAGGTGACACTATAGAAGGA
TCCGCGACCCTGTTATCCCTAGATTTAAATGATATCGG3′
330
Kana
5′AACTTTCTCCTACAGATCCCAGATAACCATGAATTTATTACACCA
TCTTGGGCGCGCCGAAGTTCCTATACTTTCTAGAGAATAGGAACTT
CGGAATAGGAACTTCAGTTGGTGATTTTGAACTTTTGCTTTGCC3′
331
Amp
5′GGACCAGTTTACAATCCCACCTGCCATCTAAGAAAGCTGGTCTCA
TCGTGGTGCCAGGGCGTGCCCTTGGGCTGGGGGCGCGGCGATCGCG
AAGTTCCTATTCCGAAGTTCCTATTCTTCAAAAGGTATAGGAACTTC
TACGGGGTCTGACGCTCAG3′
332
Amp
5′GAATTCAGAGCTCAATGAGTTGCCTTGTTCAGAGCTCTATTTTCA
CTTGACGTACGACAGACAAGCTGTGACCGTC3′
333
J Region
5′GAGTTAGGCCTCAGAGCTGAGGCAGGGCTCGGTTCCCCTTGGGTG
AGAAGGGTTTCTGTTCAGCAAGAC3′
334
J Region
5′TGGCCAATTAGAGCAAAATTTCAGACAGTAATAGGAAAAAGGTA
CTTACGTTTAATCTCCAGTCGTGTC3′
335
O2
5′TCAGTACTGACTGGAAC3′
336
O2
5′CCAATGACTTTCAAAACC3′
337
L8
5′CCGTACAGCCTGGCTC3′
338
L8
5′AACACCATCAGAGTGTGC
339
L4
5′ATGATTAATTGTGTGGACC3′
340
L4
5′AGGTGATCTCATATCCTC3′
341
A30
5′CTCAGTACTGCTTTACTG3′
342
A30
5′TGACTTCATGTCCCCTTC3′
343
L11
5′ACATGATTAATTGTGTGGACC3′
344
L11
5′GGTGCAGAGGTGACTTCG3′
345
L1
5′CTCAGTACTGCTTTACTATTC3′
346
L1
5′GAGGAACACTCTCAGCTG3′
347
L5
5′CAGGGAACTTCTCTTACAG3′
348
L5
5′GAATTAGGGTGCAGAGGC3′
349
L15
5′TACTATTCAGGGAAATTC3′
350
L15
5′TGTCTGTGAAGTTGGTG3′
351
O8
5′TGGCTCTTGATGGAAGC3′
352
O8
5′ACTTCAAAGTGTGACTGC3′
353
L19
5′AGGGAACTTCTCTTACAGC3′
354
L19
5′AATTAGGGTGCAGAGGCG3′
355
L12
5′GAAGTCTTCCTATAATATGATC3′
356
L12
5′TGGCTGCATCTGAGGACC3′
357
A20
5′GCCACTAATGCCTGGCAC3′
358
A20
5′CTGCTGTCAGCAGAGGGC3′
359
O4
5′CTTCTTATAACATGATGG3′
360
O4
5′AAACGCTCTGAGCAGC3′
361
L14
5′CTCAGTACTGCTTTACTG3′
362
L14
5′GAGGAACAATCTCAGCCG3′
363
L23
5′AGCCAGGCTGTACGGAAC3′
364
L23
5CCCAGCCTCACACATCTC3′
365
L9
5′TGGCCCTTCAGGGAAG3′
366
L9
5′ACCATCAGAGTGTGGTTG3′
367
A4
5′CCAGTGTAGCCATTAATG3′
368
A4
5′TACCAAAACTTCCCAGGG3′
369
L24
5′GGGAAATTCTCTTACTAC3
370
L24
5′CCCCCTCTACCAATAC3′
371
O6
5′CCATTCAGGGAAGTCTTC3′
372
O6
5′TGAGTCTGAGAAGTGTTG3′
373
L22
5′GGAATTTTCTTAGCCCAC3′
374
L22
5′ATGTTCAGGCTTGTAACC3′
375
A9
5′TCATCTTACAAATAGTTG3′
376
A9
5′TCTGACCATTCCTGC3′
377
A25
5′GGGAAATCATCTTATAAATAG3′
378
A25
5′TGCAGATGAGACTTCTGG3′
379
A15
5′ATTCAGGAAAGTCCTCTC3′
380
A15
5′CAGTGACCTTCAGAGTG3′
381
O9
5′ATTCAGGAAAGTCCTCTC3′
382
O9
5′CAGTGACCTTCAGAGTG3′
383
O2
5′TTGGCGCGCCTTCTGTTTCCCTTCTCAGGTGCCAGATGTGACATC
384
O2
5′CGCACGCGTGTTTGATCTCCACCTTGGTCCCTCCGCCGAAAGTGA
GAGGGGTACTGTAACTCTGTTG3′
385
L8
5′TTGGCGCGCCTTCTGTTTCCCTTCTCAGGTGCCAGATGTGACATC
386
L8
5′CGCACGCGTCCTGGGGGGTTTTTGTTAGGGCTTGTATCACTGTGG
GAGGGTAACTATTAAG3′
387
L4
5′TTGGCGCGCCTTCTGTTTCCCTTCTCAGGTGCCAGATGTGCCATC
388
L4
5′CGCACGCGTCCTGGGGGGTTTTTGTTAGGGCTTGTATCACTGTGG
GAGGGTAACTATTAAAC3′
389
A30
5′TTGGCGCGCCTTCTGTTTCCCTTCTCAGGTGCCAGGTGTGACATC3′
7
390
A30
5′CGCACGCGTCCTGGGGGGTTTTTGTTAGGGCTTGTATCACTGTGG
GAGGGTAACTATTATGC3′
391
L11
5′TTGGCGCGCCTTCTGTTTCCCTTCTCAGGTGCCAGATGTGCCATC3′
392
L11
5′CGCACGCGTCCTGGGGGGTTTTTGTTAGGGCTTGTATCACTGTGG
GAGGGTAATTGTAATC3′
393
L1
5′TTGGCGCGCCTTCTGTTTCCCTTCTCAGGTGCCAGATGTGACATC3′
394
L1
5′CGCACGCGTCCTGGGGGGTTTTTGTTAGGGCTTGTATCACTGTGG
GAGGGTAACTATTATAC3′
395
L5
5′TTGGCGCGCCTTCTGTTTCCCTTCTCAGGTTCCAGATGCGACATC3′
396
L5
5′CGCACGCGTCCTGGGGGGTTTTTGTTAGGGCTTGTATCACTGTGG
GAGGGAAACTGTTAG3′
397
L15
5′TTGGCGCGCCTTCTGTTTCCCTTCTCAGGTGCCAGATGTGACATC
398
L15
5′CGCACGCGTCCTGGGGGGTTTTTGTTAGGGCTTGTATCACTGTGG
GAGGGTAACTATTATAC3′
399
O8
5′TTGGCGCGCCTTCTGTTTCCCTTCTCAGGTGCCAGATGTGACATC
400
O8
5′CGCACGCGTCCTGGGGGGTTTTTGTTAGGGCTTGTATCACTGTGG
GAGGGAGATTATCATAC3′
401
L19
5′TTGGCGCGCCTTCTGTTTCCCTTCTCAGGTTCCAGATGCGACATC3′
402
L19
5′CGCACGCGTCCTGGGGGGTTTTTGTTAGGGCTTGTATCACTGTGG
GAGGGAAACTGTTAG3′
403
L12
5′TTGGCGCGCCTTCTGTTTCCCTTCTCAGGTGCCAAATGTGACATC3′
404
L12
5′CGCACGCGTCCTGGGGGGTTTTTGTTAGGGCTTGTATCACTGTGG
GAGAATAACTATTATAC3′
405
A20
5′TTGGCGCGCCTTCTGTTTCCCTTCTCAGATACCAGATGTGACATCC3′
406
A20
5′CGCACGCGTCCTGGGGGGTTTTTGTTAGGGCTTGTATCACTGTGG
GAGGGGCACTGTTATAC3′
407
O4
5′TTGGCGCGCCTTCTGTTTCCCTTCTCAGGTGCCAGATGTGACATC3′
408
O4
5′CGCACGCGTCCTGGGGGGTTTTTGTTAGGGCTTGTATCACTGTGG
GAGGGGCATTGTAAG3′
409
L14
5′TTGGCGCGCCTTCTGTTTCCCTTCTCAGGTGCCAGATGTAACATCC3′
410
L14
5′CGCACGCGTCCTGGGGGGTTTTTGTTAGGGCTTGTATCACTGTGG
GAGGGTAACTATTATGC3′
411
L23
5′TTGGCGCGCCTTCTGTTTCCCTTCTCAGGTGCCAGATGTGCCATC3′
412
L23
5′CGCACGCGTCCTGGGGGGTTTTTGTTAGGGCTTGTATCACTGTGG
GAGGGGTACTATAATAC3′
413
L9
5′TTGGCGCGCCTTCTGTTTCCCTTCTCAGGTGCCAGATGTGCCATC3′
414
L9
5′CGCACGCGTCCTGGGGGGTTTTTGTTAGGGCTTGTATCACTGTGG
GAGGGTAACTATAATAC3′
415
A4
5′TTGGCGCGCCTTCTGTTTCCCTTCTCAGATACCAGATGTGACATCC3′
416
A4
5′CGCACGCGTCCTGGGGGGTTTTTGTTAGGGCTTGTATCACTGTGG
GAGGGGCACTGTTATAC3′
417
L24
5′TTGGCGCGCCTTCTGTTTCCCTTCTCAGGTGCCAGATGTGTCATC3′
418
L24
5′CGCACGCGTCCTGGGGGGTTTTTGTTAGGGCTTGTATCACTGTGG
GAGGGAAACTATAATAC3′
419
O6
5′TTGGCGCGCCTTCTGTTTCCCTTCTCAGGGACCAGAAGTGACATC3′
420
O6
5′CGCACGCGTCCTGGGGGGTTTTTGTTAGGGCTTGTATCACTGTGG
GAGGGTAATTTTTATAC3′
421
L22
5′TTGGCGCGCCTTCTGTTTCCCTTCTCAGGTGTCAGATTTGACATCC3′
422
L22
5′CGCACGCGTCCTGGGGGGTTTTTGTTAGGGCTTGTATCACTGTGG
GAGGGTAACTGAAGTC3′
423
A9
5′TTGGCGCGCCTTCTGTTTCCCTTCTCAGGAGTCAGATGTGATTTCC3′
424
A9
5′CGCACGCGTCCTGGGGGGTTTTTGTTAGGGCTTGTATCACTGTGG
GATGGCTGCTGTAAG3′
425
A25
5′TTGGCGCGCCTTCTGTTTCCCTTCTCAGGAGTCAGATGTGATTTC
C3′
426
A25
5′CGCACGCGTCCTGGGGGGTTTTTGTTAGGGCTTGTATCACTGTGG
GATGGCTGCTGTAAG3′
427
A15
5′TTGGCGCGCCTTCTGTTTCCCTTCTCAGGTGCCAGATATGACATGC3′
428
A15
5′CGCACGCGTCCTGGGGGGTTTTTGTTAGGGCTTGTATCACTGTGG
GAGGGTCACTTTTATAC3′
429
O9
5′TTGGCGCGCCTTCTGTTTCCCTTCTCAGGTGCCAGATATGACATGC3′
430
O9
5′CGCACGCGTCCTGGGGGGTTTTTGTTAGGGCTTGTATCACTGTGG
GAGGGTCACTTTTATAC3′
431
V7-8
5′TTGGCGCGCC GGAGGAAACAGAAACACAG3′
432
V7-8
5′CGCACGCGT CAGCTGCTCGTCCTGGG3′
433
V11-10
5′TTGGCGCGCC GGAGGGAAACAGAAACAC3′
434
V11-10
5′CGCACGCGTAGCTGCTCCTCCTGGG3′
435
V15-14
5′TTGGCGCGCC GAAGGGAAACAGAAACACAG3′
436
V15-14
5′CGCACGCGTAGCTGCTCCTCCTGGG3′
437
V18-17
5′TTGGCGCGCC GAGGGAAACAGAAACAC3′
438
V18-17
5′CGCACGCGTCAGCTGCTGCTCCTGGG3′
439
V19-18
5′TTGGCGCGCC GAAGGGAAACAGAAACACAG3′
440
V19-18
5′CGCACGCGT AGCTGCTCCTCCTGGG3′
441
V20-19
5′TTGGCGCGCC GAGGAGGGAAACAGAAACAC3′
442
V20-19
5′CGCACGCGTCAGCTGCCCCTCCTGGG3′
443
V21-20
5′TTGGCGCGCC GGAGGAAACAGAAACACAG3′
444
V21-20
5′CGCACGCGTCCCTAGCTGCTCCTGGG3′
445
V24-23
5′TTGGCGCGCC GGAGGGAAACAGACACAC3′
446
V24-23
5′CGCACGCGTCAGCTGCTCCTCCTGGC3′
447
V26-25
5′TTGGCGCGCC GAAGGGAAAGAGAAACACAG3′
448
V26-25
5′CGCACGCGTAGCTGCTCCTCCTGGG3′
449
V27-26
5′TTGGCGCGCC GGAGGGAAACAGAAACAC3′
450
V27-26
5′CGCACGCGTCCCAGCTGCTCCTGGG3′
451
Genta
5′AGCTCGGTACCCGGGGATCCTCTAGAGTCGACCTGCAGGC
ATGCAAGCTTGGCCGGCCTGGAGTTGTAGATCCTCTACG3′
452
Genta
5′AAAACAAACCAATCAGGCAGAAACGGTGAGGAATCAGT
GAAACGGCCACTTACGGCGCGCCAAGATGCGTGATCTGATCC3′
453
Hygro
5′CGTTGGACCAGTTTACAATCCCACCTGCCATCTAAGAAAGC
TGGTCTCATATAACTTCGTATAATGTATGCTATACGAACGGTA
ACGCGTGAAGTTCCTATTCCGAAGTTCCTATTCTCTAGAAAGT
ATAGGAACTTCTCAGAGCAGATTGTACTG3′
454
Hygro
5′GGACAGCAAGCGAACCGGAATTGCCAGCTGGGGCGCCCTCT
GGTAAGGTTAAGATGCGTGATCTGATCC3′
455
5′ACTGCACCTCAGCGTCCCCCTGCCCATGTCAGGGCCGATGAA
GGGCACAGCGTACGATTACACCAGTGTCAGTAAGCG3′
456
5′TGTAATACGACTCACTATAGGGCGAATTGAGCTCGGTACCCG
GGGATCCTGCGATCGCTCAGAAGAACTCGTCAAGAAGGCG3′
457
JH
5′GTGTTATAAAGGGAGACTGAGGGAGGCAGAGGCTGTGCTA
CTGGTACCTGGCTGAATACTTCCAGCACTGGGGCCAGG3′
458
JH
5′GGCCACAGAAAAGAGGAGAGAATGAAGGCCCCGGAGAGG
CCGTTCCTACCTGAGGAGACGGTGACCGTGGTCCCTTG3′
459
Spacer
5′AACAACCTCAGGGCTGAGGACACC3′
460
Spacer
5′CTGCCCGTTGTCCCTCGAGATGGTGGCACGGCC3′
Buelow, Roland, van Schooten, Wim, Platzer, Josef
| Patent | Priority | Assignee | Title |
| Patent | Priority | Assignee | Title |
| 7129084, | Aug 03 2000 | Therapeutic Human Polyclonals, Inc | Production of humanized antibodies in transgenic animals |
| 8410333, | Jul 15 2003 | Therapeutic Human Polyclonals, Inc. | Humanized immunoglobulin loci |
| 20100286488, | |||
| 20110077965, | |||
| 20120306653, | |||
| 20130021154, | |||
| EP491057, | |||
| EP583980, | |||
| WO1992003918, | |||
| WO1997016537, | |||
| WO2000046251, | |||
| WO2000075300, | |||
| WO2001019394, | |||
| WO2002012437, | |||
| WO2004003157, | |||
| WO9716537, |
| Executed on | Assignor | Assignee | Conveyance | Frame | Reel | Doc |
| Jan 18 2005 | PLATZER, JOSEF | Therapeutic Human Polyclonals, Inc | ASSIGNMENT OF ASSIGNORS INTEREST SEE DOCUMENT FOR DETAILS | 046041 | /0023 | |
| Jan 21 2005 | BUELOW, ROLAND | Therapeutic Human Polyclonals, Inc | ASSIGNMENT OF ASSIGNORS INTEREST SEE DOCUMENT FOR DETAILS | 046041 | /0023 | |
| Jan 26 2005 | SCHOOTEN, WIM VAN | Therapeutic Human Polyclonals, Inc | ASSIGNMENT OF ASSIGNORS INTEREST SEE DOCUMENT FOR DETAILS | 046041 | /0023 | |
| Feb 09 2016 | Therapeutic Human Polyclonals, Inc. | (assignment on the face of the patent) | / |
| Date | Maintenance Fee Events |
| Jul 15 2021 | M1552: Payment of Maintenance Fee, 8th Year, Large Entity. |
| Date | Maintenance Schedule |
| Nov 20 2021 | 4 years fee payment window open |
| May 20 2022 | 6 months grace period start (w surcharge) |
| Nov 20 2022 | patent expiry (for year 4) |
| Nov 20 2024 | 2 years to revive unintentionally abandoned end. (for year 4) |
| Nov 20 2025 | 8 years fee payment window open |
| May 20 2026 | 6 months grace period start (w surcharge) |
| Nov 20 2026 | patent expiry (for year 8) |
| Nov 20 2028 | 2 years to revive unintentionally abandoned end. (for year 8) |
| Nov 20 2029 | 12 years fee payment window open |
| May 20 2030 | 6 months grace period start (w surcharge) |
| Nov 20 2030 | patent expiry (for year 12) |
| Nov 20 2032 | 2 years to revive unintentionally abandoned end. (for year 12) |